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Psoriasis is an immune-mediated skin disorder that is inherited as a complex trait. 
Genome-wide linkage and association studies have identified a major disease 
susceptibility locus (PSORS1) and several genetic determinants of smaller effect. At 
least two of these (the IL12B and IL23R genes) have independently been associated with 
Crohn’s disease (CD). Thus, the aim of this project was to investigate the genetic 
overlap between psoriasis and CD, with a view to identifying shared pathogenic 
pathways.  
In the first phase of the study, 26 CD variants were genotyped in 1,256 psoriatic patients 
and 2,938 unaffected individuals. Significant associations (FDR < 0.01) were observed 
for three markers, mapping to chromosomes 6p22, 21q21 and 21q22. The analysis of an 
independently ascertained dataset (1,348 cases vs. 1,368 controls) validated the 
chromosome 6p22 association, with the critical SNP (rs6908425) yielding a combined P 
value of 4 x 10-6. This marker lies within the CDKAL1 gene, which also harbours type 2 
diabetes (T2D) associated alleles. 
Since the mechanisms mediating the pathogenic effect of CDKAL1 are poorly 
understood, an investigation into gene function was undertaken in the second part of the 
study. Real-time PCR analyses of multiple cDNA panels showed that CDKAL1 is 
abundantly expressed in immune cells, especially in CD4+ and CD19+ lymphocytes. 
Stable CDKAL1 knock-down cell lines generated by sh-RNA lentiviral transduction 
were also analysed. This showed that CDKAL1 silencing results in reduced cell 
proliferation and altered cell cycle progression. Transcription profiling of the knock-
down cells identified a number of differentially expressed genes, mostly involved in 
housekeeping functions and inflammatory responses.  
Taken together, these findings indicate that CDKAL1 is a pleiotropic gene conferring 
 II
susceptibility to psoriasis, CD and T2D. The results of functional studies suggest that 
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Chapter 1: General introduction 
 
1.1 The immune system  
 
The immune system protects the organism against the attack of pathogens through a 
variety of recognition systems and effector mechanisms that seek out and destroy 
invading microorganisms. This is achieved by means of two main types of immune 
responses known as innate and adaptive immunity (Table 1.1.1).  
 
1.1.1 Innate immunity 
Innate immunity is the first response of the immune system against any microbial 
attack. It is an evolutionary conserved mechanism of defence against invading 
microorganisms, which is also found in plants, insects, fungi and in primitive 
multicellular organisms (Beck and Habicht 1996). 
 
1.1.1.1 Innate immune receptors  
 
The innate immune system senses the presence of phatogenes by means of specialized 
receptors, which recognize microbe-specific molecules. These sensors are known as 
pattern recognition receptors (PRRs) and their ligands are referred to as pathogen-
associated molecular patterns (PAMPs). PRRs can be divided into three main families: 
Toll-like receptors, RIG-I-like receptors and NOD-like receptors. 
 
1.1.1.1.1 Toll-like receptors 
Toll-like receptors (TLRs) are evolutionary conserved membrane-bound proteins 
located on the cell surface (TLR- 1, 2, 4, 5, 6 and 10), or in endosomes (TLR- 3, 7, 8 
and 9). They are formed by a ligand-binding domain containing 19-25 consecutive 
leucine-rich repeats (LRR), a membrane spanning domain and a conserved signalling 
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motif, known as the Toll-interlukin-1 receptor (TIR) domain. TLRs recognize 
evolutionary conserved features present on the cell walls of pathogens (e.g. lipoproteins 
and peptidoglycan), as well as viral nucleic acids. Following ligand recognition, TLRs 
activate two different cascades known as the MyD88-dependent and the TRIF-
dependent pathway. The former results in the activation of the pro-inflammatory 
transcription factor NF-țB, whereas the latter leads to the production of type I 
interferons (IFNs) (Kawai and Akira 2008; Fukata, Vamadevan et al. 2009). 
 
1.1.1.1.2 RIG-I like receptors  
RIG-I-like receptors RLRs form a second group of PRRs that are able to recognize viral 
nucleic acids. RLRs reside in the cytoplasm and include the RIG-I (retinoic acid-
inducible gene-I) and MDA-5 (melanoma differentiation-associated gene-5) receptors. 
Both share the same molecular structure, including two amino-terminal Capase 
Recruitment Domains (CARDs), a central ATPase and helicase domain, and a carboxy 
C-terminal regulatory motif. Upon binding of viral RNA, RLRs signal through the IPS-
1 adaptor and induce the production of type I IFNs, through the activation of IRF3 and 
NF-NB (Kawai and Akira 2008; Nakhaei, Genin et al. 2009). 
 
1.1.1.1.3 NOD-like receptors  
NOD-like receptors (NLRs) are soluble cytosolic proteins, which recognise pathogens 
and molecules released during cell damage or stress. The 23 NLRs that are encoded by 
the human genome can be classified in two main subfamilies: NOD (nucleotide-binding 
oligomerization domain) and NALP (NACHT, LRR and PYD containing proteins) 
proteins. These share two common domains: the ligand-sensing LRRs and the NACTH 
(named after the NAIP, CIITA, HET-E and TP-1 proteins, where it is present) 
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oligomerization motif. However, NOD and NALP proteins differ in the make-up of their 
effector regions, which consist of a CARD and a PYD (effector pyrin domain) domain, 
respectively. Following ligand recognition, NOD receptors activate NF-țB and 
mitogen-activated protein kinase (MAPK) signalling, whereas NALPs cause the 
cleavage of the pro-inflammatory precursors pro-IL-1ȕ and pro-IL-18 into their mature 
forms, through activation of caspase 1 and 5 (Fukata, Vamadevan et al. 2009).  
 
1.1.1.2 Innate immune cells 
 
1.1.1.2.1 Keratinocytes  
The first line of defence against invading pathogens is provided by anatomical barriers, 
such as the skin. Keratinocytes (KCs), which are the predominant cell type in the 
epidermis (i.e. the skin upper layer), not only contribute to the integrity of the skin 
barrier but also participate in innate immune responses. In fact, KCs express most TLRs 
and RLRs, as well as a variety of NLRs (Miller and Modlin 2007; Miller and Modlin 
2007; Harder and Nunez 2009). Upon PAMP recognition, these receptors trigger the 
production of anti-microbial peptides (e.g. ȕ-defensins and chatelicidins) and pro-
inflammatory mediators (e.g. cytokines and chemokines) (Nestle, Di Meglio et al. 
2009). 
 
1.1.1.2.2 Macrophages and neutrophils  
Macrophages and neutrophils are two early effectors of the innate immune response, 
which are stimulated through the activation of their TLRs. 
Macrophages are mononuclear white cells resident within tissues. They differentiate 
from monocytes, which are their circulating progenitors and are found at a 
concentration of 500 to 1,000 per mm3 of blood. 
Neutrophils are part of the granulocyte family of polymorphonuclear leukocytes. These 
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are very abundant in the blood as they are present at a concentration of 4,000 to 10,000 
per mm3. This number can rapidly increase to 20,000 per mm3 in the presence of an 
infection. This cell type can easily invade extra-vascular tissues at infection sites by 
binding to endothelial adhesion molecules such as selectin, integrin, ICAM-1 and 
ICAM-2 and responding to chemoattractants (Lawrence and Springer 1991; Teng, 
Johkura et al. 2003). 
Both macrophages and neutrophils are phagocytes, i.e. cells that engulf microbes by 
extending and wrapping part of their plasma membrane around invaders. Once the 
microbes are internalized, they are attacked by several enzymes (e.g. phagocyte oxidase, 
inducible nitric oxide synthase and lysosomal proteases) activated within lysosomes and 
phagolysosomes. 
 
1.1.1.2.3 Natural Killer cells  
Natural Killer (NK) cells are a small population of immune cells, which account for 5-
10% of circulating lymphocytes and which represent the first line of defence against 
viruses. NK cells have cytolytic activity towards infected cells, which they recognize, 
based on abnormalities in the profile of surface antigens. Moreover, activated NK cells 
produce a variety of cytokines, most notably TNF-D and IFN-Ȗ. These two cytokines 
promote dendritic cell maturation with a consequent enhancement of antigen 
presentation to T cells (see section 1.1.2.2). IFN-Ȗ has also a powerful effect on 
macrophage activation. Thus, NK cells contribute to shaping the overall host immune 





1.1.1.2.4 Dendritic cells  
Dendritic cells (DCs) are the professional antigen presenting cells (APC). They 
continuously circulate between the bloodstream and the tissues that are most exposed to 
the external environment, i.e. the skin and the epithelia lining the lung and the gastro-
intestinal tract. Several types of DCs are known. Langherhans cells (LCs), which 
express the CD1a and CD207 (langerin) surface markers, are found in the epidermis and 
in lymph nodes. Although LCs have previously been considered to be antigen 
presenting cells, more recent work suggest that they may also act as immune modulators 
in-vivo (Kaplan, Jenison et al. 2005). 
Dermal myeloid dendritic cells (mDCs), which express the surface marker CD1c, 
differentiate from circulating monocytes that are recruited to the dermis under 
inflammatory conditions. mDCs are antigen presenting cells, which also contribute to 
the fight against infection, through the production of cytokines and chemokines 
(Auffray, Sieweke et al. 2009). 
Plasmacytoid DCs (pDCs), which express the BDCA-2 surface marker, differentiate 
from plasmacytoid precursors. pDCs produce high amounts of IFN-Į upon exposure to 
viral nucleic acids and activation of TLR7 and TLR9 (Nestle, Conrad et al. 2005).  
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Table 1.1.1: Properties of innate and adaptive immune responses 
Adapted from (Mayer 2006) 
 Innate response Adaptive response 
Recognition mechanism Direct Indirect (mediated by 
antigen presentation) 
Specificity Limited High 
Onset of response Immediate (hours) Delayed (days) 
Immunological memory Absent Present 
Self-recognition Absent Rare 
Clonal expansion Absent Present 
Organisms Nearly all multi-cellular 
organisms 
 

















1.1.2 Adaptive immunity  
 
The adaptive immune system provides a response against pathogens when innate 
mechanisms are no longer able to contain an infection. Its action is based on antigen-
specific recognition of invaders and is also characterized by the key features of memory 
and delayed onset. These properties distinguish it from innate immunity (Table 1.1.1). 
Acquired immunity is dependent on a highly specialized set of cells known as 
lymphocytes. These are an extremely heterogeneous population divided in two different 
groups, T and B cells which respectively differentiate from their precursors, in the 
thymus and in the bone marrow.  
 
1.1.2.1 B lymphocytes and the humoral response  
B cells are key players of the humoral response, i.e. the production of antibodies 
mediating the destruction of extracellular microorganisms. Immature B lymphocytes are 
activated into proliferating and antibody-secreting plasma cells, through their exposure 
to antigens in lymphoid secondary organs (most notably the spleen and lymph nodes). B 
cell activation leads to a change in the heavy chain class of the antibody that is 
produced, a process known as class switching. B cell activation can also result in the 
phenomenon of affinity maturation, whereby the affinity of the antibody for its antigen 
increases progressively.  
The antibodies secreted by plasma cells and memory B cells have three main effector 
functions. First, antibodies promote opsonisation, a process whereby phagocytes 
expressing the FcR heavy chain receptor bind the constant region of Ig molecules and 
internalize pathogens. Secondly, antibodies activate the complement pathway, a highly 
regulated cascade of proteolytic cleavage reactions, which results in the lysis of foreign 
cells. Finally, the interaction of antibodies with Fc receptors expressed on a variety of 
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effector cell types can trigger their cytotoxic activity, in a process known as antibody-
dependent cell-mediated cytotoxicity (Manabu 2010).  
 
1.1.2.2 T lymphocytes and antigen presentation  
T cells can be classified into two main subsets, which can be distinguished on the basis 
of the surface markers they express. CD4+ T helper cells (Th) are mainly involved in the 
activation of other immune cell types, whereas CD8+ cytotoxic T lymphocytes (Tc) have 
direct cytolytic activity towards infected cells. A third lymphocyte population is 
represented by CD4+CD25+ regulatory T cells (Treg), which suppress the activation of 
the immune system. 
T lymphocytes can only participate to immune responses through the process of antigen 
presentation, whereby peptides bound to Major Histocompatibility Complex (MHC) 
proteins are presented to T the cell receptor by macrophages, DCs and B cells. In 
general, class I MHC molecules, which are expressed on most nucleated cells, 
participate to the presentation of endogenous antigens to CD8+ Tc cells (Banchereau, 
Briere et al. 2000; Hansen and Bouvier 2009). Conversely, class II MHC molecules, 
which are restricted to B cells, macrophages and DCs, participate to the presentation of 
exogenous antigens to CD4+ Th cells (Banchereau, Briere et al. 2000) (Fig. 1.1.2.2.1).  
 
1.1.2.2.1 T helper cell subsets  
Activation of Th cells through antigen presentation generates three different effector 
populations, known as Th1, Th2 and Th17 (Fig.1.1.2.2.1.1). 
Th1 cells are major producers of IFN-Ȗ, which stimulates the activity of macrophages 
and Tc cells. Th2 cells produce IL-4, which stimulates class-switching in B 
lymphocytes. Th2 cells also release IL-13 and IL-5, which respectively attract basophils 
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and eosinophils (Moser and Murphy 2000; Eisenbarth, Piggott et al. 2003).  
Th17 cells are the main producers of IL-17 and IL-22, two cytokines which drive the 
recruitment of neutrophils to sites of inflammation (Dong 2008; Martinez, Nurieva et al. 





Figure 1.1.2.2.1: Antigen processing and presentation 
(A) Antigen presentation via MHC class II molecules. Exogenous antigens are initially 
degraded in the endosome and then directed into the late endosomal/lysosomal 
compartment, where they interact with MHC molecules. The peptide-MHC complex is 
next transported to the cell surface, and presented to the T-Cell Receptor (TCR). This 
interaction is further stabilized by the presence of the CD4 molecule.  
(B) Antigen presentation via MHC class I molecules. Endogenous antigens are 
degraded by the proteasome and the resulting peptides are delivered to the endoplasmic 
reticulum (ER) by transporter associated with antigen processing (TAP). The peptide-
MHC complex which forms in the ER is transported to the cell surface via the Golgi 
apparatus. The antigen is presented to the TCR. This interaction is further stabilized by 
the CD8 molecule. 























Figure 1.1.2.2.1.1: Differentiation of Th cell subsets 
Naïve T cells differentiate into distinct effector subsets, in the presence of different 
cytokines. Differentiation to Th1 status occurs in the presence of IL-12 and IFN-Ȗ, 
through the activation of the transcription factor T-bet. Th1 cells express the surface 
chemokine receptors CXCR6, CXCR5, and CCR3. Th2 differentiation is dependent on 
the presence of IL-4 and the activation of the STAT6 and STAT3 transcription factors. 
Committed Th2 cells express CCR4, CXCR3 and CCR8.  
Th17 differentiation requires the action of TGF-ȕ1, IL-1ȕ, IL-6 and IL-21, as well as the 
activation of the RORC2 transcription factor. Th17 cells express CCR4, CCR6 and 
CD161, as well as IL23R. 




1.2 The structure of skin 
The skin is the largest organ of the human body and accounts for approximately 15% of 
its weight. It defends the body against microbial pathogens, as well as chemical and 
physical insults. The skin is composed of two layers, known as the epidermis and the 
dermis. 
 
1.2.1 The epidermis  
The epidermis (from the Greek epi, on top and derma, the skin) represents the 
outermost compartment of the skin. It consists of five strata through which 
keratinocytes migrate as they differentiate. The stratum basale is the bottom layer of the 
epidermis and is formed by a single row of basal keratinocytes, which constantly 
proliferate by mitosis. As these cells differentiate, they move into the stratum spinosum, 
which consists of 8-10 layers of cells connected by desmosomes. The subsequent layer 
is the stratum granulosum, which is formed by 2-4 rows of keratinocytes. These cells 
have a darker cytoplasm due to the presence of keratoyalin granules. The stratum 
lucidum is a thin layer that is only apparent in the soles of the feet and palms of the 
hands. It is composed by flatted keratinocytes filled with eladin, a substance which is 
similar to keratin. The terminal differentiation of keratinocytes is completed in the 
stratum corneum, which is composed of anucleated, flattened dead cells, filled with 







1.2.2 The dermis  
The dermis consists of two layers known as stratum papillare and stratum reticulare. 
The stratum papillare is rich in lymph and blood vessels, sensory nerve endings, hair 
follicles and glands. It can protrude into the epidermis through finger-like projections 
known as dermal papillae. The stratum reticulare provides mechanical strength and 
elasticity to the skin. These characteristics are conferred by a network of fibroblasts, 
collagenous, elastic and reticular fibres (Cristopher 2010). 
 
1.2.3 Skin resident immune cells  
As the skin is continuously exposed to environmental pathogens, it hosts a large 
population of resident immune cells, including Langherans cells (LCs), dermal mDCs, 
macrophages and T cells. 
LCs and dermal mDCs are antigen presenting cells that participate to inflammatory 
responses through the release of cytokines and chemokines. A subtype of mDC is 
specialised in the release of TNF-Į and inducible nitric oxide synthase. These cells are 
known as TIP (TNF-Į and iNOS producing) and play an important role in the fight 
against bacterial infections (Serbina, Salazar-Mather et al. 2003). 
Dermal macrophages (dMɎ) can be classified into the MɎ1 and MɎ2 sub-populations, 
which promote Th1 and Th2 responses, respectively (Mantovani, Sica et al. 2004).  
Twice as many T cells are present in the skin than in peripheral blood. CD8+ T cells are 
mainly found in the epidermis and CD4+ T cells in the dermis. These lymphocytes are 
the body’s first line of defence against antigenic challenges and play a key role in 
maintaining the skin immune homeostasis (Nestle, Di Meglio et al. 2009). 
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 Figure 1.2.1.1: The structure of skin 
The dermis and the epidermis host a variety of cell types. The epidermis is mainly 
composed of keratinocytes, but the stratum basale also includes melanocytes, the 
melanin-producing cells that protect the organism from ultraviolet radiation. Likewise, 
the stratum spinosum contains LCs, as well as keratinocytes. The dermis is mainly 
composed of fibroblasts, but it also contains macrophages, dermal mDCs, sebaceous 
and sweat glands, hair follicles and blood vessels. 






1.3 The gastrointestinal mucosa  
1.3.1 Histology of the gastrointestinal tract  
The gastrointestinal (GI) tract comprises the various organs that extract energy and 
nutrients from food, while expelling unwanted waste. The upper GI tract includes the 
oesophagus, stomach and duodenum. The lower GI tract consists of the remaining part 
of the small intestine (jejunum and ileum) and of the entire large intestine (cecum, colon 
and rectum).  
At the histological level, the GI tract can be divided into four layers known as mucosa, 
submucosa, muscularis externa, and adventitia. The innermost layer is the mucosa, 
which is involved in the digestion and absorption of nutrients. The mucosa consists of 
three further layers: ephithelium, lamina propria, and muscularis mucosae. The 
submucosa is a large, irregular connective tissue layer, characterized by the presence of 
blood and lymphatic vessels, as well as nerves. The submucosa is also the site of 
Meissner`s plexus, a network of parasympathetic ganglia that innervates the muscularis 
mucosae. The Muscularis externa is composed of two smooth muscle layers (an inner 
circular one and a longitudinal external one), which are innervated by Auerbach`s 
plexus. Finally, the adventitia is the external connective tissue the covers the muscularis 
externa. When this layer faces the peritoneal cavity, it becomes covered by mesothelium 















Figure 1.3.1.1: Anatomy and histology of the gastrointestinal tract 
(A) Schematic representation of the gastrointestinal tract (GI) showing the various 
organs that make up the digestive system. (B) Histological structure of the GI tract. The 
position of the various tissue layers described in section 1.3.1 is shown. (C) Key players 
in the GI immune system. The epithelial layer lining the mucosa contains globet and 
Paneth cells, as well as Microfold cells (M cells) and DCs which sample the luminal 
environment for pathogens. Upon exposure to external agents DCs migrate to the 
mesenteric lymph nodes, where they activate naïve T cells. 


















1.3.2 The mucosal barrier  
The epithelium lining the GI tract mucosa forms a barrier which protects the organism 
against pathogens and dietary antigens, while allowing nutrient absorption, fluid 
exchange and waste secretion. The first line of defence against microorganisms is 
provided by mucins, a family of heavily glycosylated proteins that are secreted by 
specialized goblet cells. Mucins form a hydrated gel that prevents bacteria from coming 
into contact with the epithelium of the mucosa. Bacteria are also contrasted by Paneth 
cells, another set of specialized epithelial cells, which fight infections by secreting 
antimicrobial defensins. A final layer of protection is provided by tight and adherens 
junctions, which seal the space between cells. Of note, the function of tight junctions 
can be affected by inflammatory cytokines, such as TNF-Dand IFN-J (Turner 2009). 
 
1.3.3 The mucosal immune system  
The defence against infections is of particular importance in the intestinal tract, which is 
the body’s largest mucosal surface. An important role is played by Peyer’s patches, 
which are the specialized lymphoid nodules of the small intestine. These are sites where 
Microfold cells (M cells) deliver antigens to a variety of DC subsets, via transepithelial 
vesicular transport. Antigen presentation by DCs results in activation of Th1 and Th17 
effector cells. T cells that have been activated by DCs can also migrate into the lamina 
propria and the epithelium, where they differentiate into cytotoxic T cells.  
The GI tract also hosts a population of IgA-producing plasma cells that reside in the 
lamina propria. The IgA molecules secreted by these cells are transported across the 
epithelium and into the gut lumen, where they provide another line of defence against 
pathogens (Strober, Fuss et al. 2002). 
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1.4 Identification of complex disease susceptibility genes 
Genetic factors play an important role in the pathogenesis of most common diseases. In 
the last few years, the availability of the human genome sequence (Lander, Linton et al. 
2001; Venter, Adams et al. 2001) and the advent of high-throughput genotyping 
technologies have allowed geneticists to make significant progresses in elucidating the 
inherited basis of disease susceptibility.  
 
1.4.1 The genetic component of complex traits  
Assessing the role played by genetic factors is a first, essential step in the analysis of 
any complex trait. Historically, this has been achieved through epidemiological surveys 
investigating the familial aggregation of diseases or their concordance rates in 
monozygotic and dizygotic twins. The results of these studies have informed the 
calculation of parameters such as the Os (a measure of the increase in disease risk 
among siblings of affected patients), or h2 (an index of the proportion of phenotypic 
variance that can be attributed to genotypic variance), which can be used to quantify the 
magnitude of the genetic component underlying a given phenotype (Strachan 2004). 
 
1.4.2 Genome-wide linkage studies  
A classical procedure for determining the chromosomal location of a disease gene is the 
linkage study, where the co-segregation of markers and disease phenotypes is assessed 
across pedigrees. Linkage studies have been used with great success in the genetic 
analysis of monogenic disorders, but have mostly generated inconclusive results, when 
applied to non-Mendelian conditions. In fact, linkage methods rely on the accuracy of 
the inheritance model that is used to analyse the data. When the genetic architecture of a 
disease is unknown, linkage performs very poorly (Strachan 2004). Moreover, it has 
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been established that linkage affords very limited power for the detection of common 
variants of small phenotypic effect (Risch 2000). For these reasons, linkage analysis had 
very limited success in uncovering complex disease susceptibility alleles, so much so, 
that the identification of NOD2 mutations in CD (Hugot, Chamaillard et al. 2001; 
Ogura, Bonen et al. 2001), is considered one of the very few genuine findings emerging 
from these studies.  
 
1.4.3 Genome-wide association studies (GWASs) 
Association studies are based on the comparison of case and control allele frequencies. 
Although theoretical calculations had long established that this approach had adequate 
statistical power for the detection of small phenotypic effects (Risch 2000), the practical 
implementation of genome-wide association studies (GWASs) had to await the 
development of platforms for high-throughput genotyping and the availability of 
sufficient information on the human genome variation content.  
 
1.4.3.1 The HapMap Project  
The HapMap project was launched in 2002 with the objective of cataloguing DNA 
sequence variants in individuals of different ethnicity. The project is being implemented 
in three sequential phases. Two-hundred and sixty-nine individuals of European, African 
and Asian descent were analysed in phase I and genotypes were obtained for more than 
1x106 Single Nucleotide Polymorphisms (SNPs), occurring with a minor allele 
frequency > 0.05. These data provided a general picture of Linkage Disequilibrium 
(LD) conservation across the human genome (The International HapMap Consortium 
2005). In phase II, genotyping was extended to include more than 3.1 x 106 SNPs, thus 
generating a comprehensive and freely accessible genetic resource for the selection of 
markers to be used in GWASs (Frazer, Ballinger et al. 2007). Finally, in phase III the 
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study population was extended to include a total of 1,184 individuals, the genotypes of 
which formed the basis for an integrated dataset, including information on common and 
rare alleles, as well as copy-number variation (CNV) (Altshuler, Gibbs et al. 2010).  
 
1.4.3.2 The 1,000 Genome Project  
The 1,000 Genomes Project was launched in 2008, with the aim of exploiting next-
generation sequencing technologies in order to generate a comprehensive catalogue of 
human genetic variation (including 95% of variants occurring at > 0.01 frequency in 
non-coding regions and > 0.001 frequency in coding exons), in five major population 
groups (originating from Europe, East Asia, South Asia, West Africa and the Americas). 
This objective is being pursued by low coverage sequencing of the entire genome and 
deep targeted sequencing of all coding regions (The 1000 Genome Project Consortium 
2010).  
 
1.4.3.3 Experimental design of GWASs  
A typical GWAS consists of several steps, the first of which is the ascertainment of 
patient and control datasets. In this context, the choice of the controls that will be 
matched with cases is of great importance, as pairing with controls from different ethnic 
groups will lead to spurious associations. One of the approaches that are currently being 
used is the analysis of well characterized, prospectively ascertained resources such as 
the 1958 British Birth Cohort (Power and Elliott 2006). 
Once the cases and controls have been recruited, DNAs are genotyped on commercially 
available platforms, the design of which may be informed by the nature and position of 
SNPs (gene-centred approach) or the information generated by the HapMap project 
(indirect approach). The genotype data are next subject to stringent quality controls (e.g. 
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the analysis of Hardy-Weinberg equilibrium and SNP call rates) to eliminate inaccurate 
calls. Data can also be derived for markers that have not been experimentally analysed, 
using imputation methods to predict SNP genotypes based on those of neighbouring 
markers (Howie, Donnelly et al. 2009). Association tests are next performed and 
replication of significant findings is sought in an independent resource. Because of the 
extensive multiple testing carried out in these studies, novel associations can only be 
declared if they meet the so-called threshold for genome-wide significance (P < 5 x 10-
8) (Pearson and Manolio 2008). 
Meta-analyses can also be carried out across different GWASs, in order to uncover 
subtle effects that can only be identified through the analysis of very large samples. 
 
1.4.3.4 Successes and limitations of GWASs 
The GWASs carried out in the last few years have identified hundreds of disease 
susceptibility genes, revolutionizing our understanding of common disease genetics. 
Despite these huge steps forward, a substantial portion of complex disease heritability 
remains unaccounted for (Maher 2008). This is thought to reflect, at least in part, the 
limitations of GWASs, which are typically designed to identify common SNPs and are 
unlikely to detect the effects of rare variants and CNVs (Maher 2008). 
 
1.4.4 Follow-up of association signals 
It is important to emphasize that GWASs identify disease susceptibility intervals that 
typically include more than one gene. Even when that is not the case, the disease 
associated SNPs that are detected within a given gene are unlikely to include the causal 
susceptibility allele. Thus, the results of GWASs need to be followed-up by further 




1.4.4.1 Fine mapping of disease susceptibility intervals 
The fine mapping of association signals used to require the re-sequencing of large 
genomic segments, an expensive and labour-intensive step that was necessary to 
catalogue all the genetic variation found in a given disease susceptibility interval. 
Thanks to the efforts of the 1,000 Genomes and the HapMap projects, this data is now 
freely available to the scientific community and is being used for the design of custom 
genotyping platforms. The most notable example is the Immunochip genotyping array, 
which includes 200,000 SNPs, spanning 186 distinct loci identified in immune disease 
GWASs. The Immunochip will be used for the analysis of a variety of case-control 
datasets and is expected to identify the causal susceptibility alleles underlying 
conditions such as Crohn’s disease, celiac disease, multiple sclerosis, psoriasis, and type 
1 diabetes. 
 
1.4.4.2 Functional studies 
There have been many instances where GWASs have identified disease susceptibility 
genes of unknown function. Investigating the physiological and pathological role of 
these genes remains a lengthy and laborious task, which is often complicated by the 
necessity of generating and validating the required laboratory reagents. These include 
cDNA constructs and antibodies, but also stable knock-down cell lines or knockout 
organisms. 
Even when the function of a disease gene is well known, dissecting the impact of the 
causal susceptibility allele can be challenging. The most notable successes have been 
obtained in ex-vivo studies, where gene-expression levels or immune responses were 
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compared in healthy individuals bearing different genotypes at the locus of interest 
(Dendrou, Plagnol et al. 2009; Di Meglio, Di Cesare et al. 2011). This underscores the 
importance of well characterized healthy donor panels (e.g. the Cambridge 
BioResource, including 9,000 individuals who donated their DNA and agreed to be re-




































1.5.1 Clinical presentation 
Psoriasis is a chronic and relapsing immune-mediated skin disease that affects 2-3% of 
the Caucasian population and 0.4-0.7% of individuals of African and Asian descent 
(Christophers 2001; Nestle, Kaplan et al. 2009). 
The disorder affects both sexes with equal frequency and the onset of symptoms shows 
a bimodal distribution peaking at 15-30 and 50-60 years of age. In this context, the 
disease can be triggered by a variety of environmental factors, including exposure to 
certain drugs (e.g. lithium and beta-blockers), streptococcal infections, skin trauma and 
stress (Griffiths and Barker 2007). 
Several subtypes of the disease have been described, including psoriasis vulgaris, as 
well as erytrodermic, guttate, palmoplantar and nail psoriasis.The most common form 
of the disease (affecting ~ 90% of patients) is psoriasis vulgaris, which is characterised 
by the occurrence of red plaques that may vary in size and yet are well delimited from 
the normal skin. Generally, these lesions are localized on elbows, knees, scalp, 
lumbosacral region, trunk and lower extremities (Fig. 1.5.1.1) (Griffiths, Christophers et 
al. 2007). 
The main histological features of psoriatic plaques are epidermal hyperplasia, 
angiogenesis, altered differentiation of keratinocytes and infiltration of mononuclear 
leukocytes in the dermis and the epidermis (Griffiths and Barker 2007). 
Whilst rarely fatal, the disorder has a profound impact on patient well-being, with 
substantial psychological consequences. Several studies have also reported an 
association with a number of significant co-morbidities, including psoriatic arthritis (a 
potentially disabling form of joint inflammation), Crohn’s disease (CD), myocardial 
infarction (MI), type 2 diabetes (T2D), dyslipidemia and obesity (Najarian and Gottlieb 
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2003; Wolters 2005; Gelfand, Neimann et al. 2006; Shapiro, Cohen et al. 2007). 
Different therapeutic approaches are now available for the treatment of psoriasis. These 
include the use of topical (e.g. corticosteroids, calcipotriene, and tazarotene), systemic 
(e.g. retinoids, methotrexate and cyclosporine) and biologic agents (e.g. anti-TNF 
antibodies). The choice between these options is dependent on the severity of disease 
and the occurrence of potential side-effects (Gottlieb, Korman et al. 2008; Menter, 
Gottlieb et al. 2008). Of note, although the treatments outlined above can improve the 
condition of patients none can cure the disease (Gottlieb, Korman et al. 2008; Menter, 















 Figure 1.5.1.1: Clinical presentation of psoriasis 
Psoriatic lesions occur in different shapes and sizes. Lesions, which tend to be 
symmetric, can cover a substantial portion of the body surface. Nails can also be 
affected (last photo on the right). 


















The main cell types found in psoriatic plaques are KCs, DCs, macrophages and T 
lymphocytes (Barker, Mitra et al. 1991; Nestle, Turka et al. 1994; Nickoloff 1999). 
In psoriatic lesions, hyper-proliferating KCs reach the stratum corneum of the epidermis 
while their differentiation is still incomplete. These cells are activated by infiltrating T 
lymphocytes and release cytokines, angiogenic factors (e.g. vascular endothelial growth 
factor, VEGF), adhesion molecules (e.g. intercellular adhesion molecule 1, ICAM-1), 
and antimicrobial peptides (e.g. LL-37 and defensins). Of note, the antimicrobial 
peptide LL-37 can bind self-DNA to form aggregate structures that trigger type I IFN 
production in pDCs, via activation of TLR9 (Lande, Gregorio et al. 2007). Given that 
the release of type I IFN from pDCs is an early pathogenic event in psoriasis (Nestle, 
Conrad et al. 2005), the loss of innate tolerance to self-DNA is now thought to be one of 
the drivers of autoimmunity in psoriasis (Lande, Gregorio et al. 2007).  
Lesional mDCs produce high levels of IL-2 and IFN-Ȗ, thus contributing to Th1 
responses (Chu, Di Meglio et al. 2011). mDCs can also sense LL-37/self-RNA 
complexes via TLR8, thus driving the production of the pro-inflammatory cytokines 
TNF-D and IL-6 (Ganguly, Chamilos et al. 2009).  
Macrophages are found in increased numbers in psoriatic skin, especially at the 
epidermal/dermal interface (Clark and Kupper 2006). Studies carried out in mouse 
models of the disease indicate that these cells are a significant source of TNF-D (Clark 
and Kupper 2006; Stratis, Pasparakis et al. 2006; Wang, Peters et al. 2006). These 
studies have also shown that the activation of macrophages requires the presence of T 
cells, an observation that is in agreement with the widespread view that psoriasis is a T 
cell-mediated disease. In fact, T cells numbers are dramatically increased in psoriatic 
skin, with CD4+ and CD8+ lymphocytes infiltrating the dermis and the epidermis, 
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respectively. Th1 and Th17 cell numbers are especially elevated in psoriatic plaques and 
the cytokines they produce are over-expressed (Kagami, Rizzo et al. 2010).  
Of note, the cytokines released by Th17 cells promote keratinocyte proliferation as well 
as production of microbial peptides (Liang, Tan et al. 2006). Thus the interaction 
between T cells and KCs is crucial to the onset and maintainance of chronic skin 











 Figure 1.5.2.1: Overview of the events leading to the onset of psoriasis 
In psoriatic skin, inflammation is mediated by a crosstalk between cells of the innate 
and adaptive immune system. The cytokines released by activated KCs (TNF-D, IL-6, 
IL-1ȕ) and pDCs (IFN-Į) lead to the maturation of dermal dendritic cells (DDC). These 
migrate to lymph nodes, where they promote the differentiation of Th1 and Th17 cells. 
The cytokines produced by these activated lymphocytes (IFN-Ȗ, IL-17, IL-22) stimulate 
KC activation, in a positive feedback look that amplifies and sustains chronic skin 
inflammation. 






1.5.3 Genetics of psoriasis 
The existence of a genetic component for psoriasis is supported by repeated 
observations of family disease clustering and higher disease concordance in 
monozygotic compared to dizygotic twins (Brandrup, Holm et al. 1982; Roberson and 
Bowcock 2010). On this basis, psoriasis has long been considered as a multifactorial 
disease caused by gene-gene and gene-environment interactions. 
 
1.5.3.1 The PSORS1 locus  
In the last 15 years, linkage and association studies have repeatedly identified a major 
disease susceptibility locus, known as PSORS1 (Psoriasis Susceptibility 1) and lying 
with the Major Histocompatibility Complex (MHC) on chromosome 6p21.3 (Nair, 
Henseler et al. 1997; Trembath, Clough et al. 1997; International Psoriasis Genetics 
Consortium 2003). The susceptibility region has been subsequently refined to a 300 kb 
DNA segment encompassing part of the MHC class I region (Veal, Capon et al. 2002; 
Fan, Yang et al. 2008). Several genes lie in this interval, including HLA-C, PSORS1C3, 
POU5F1, TCF19, CCHCR1, SPR1, SEEK1, CDSN and STG (Fig. 1.5.3.1.1). Of these, 
the HLA-C, CDSN and CCHCR1 genes are very polymorphic and carry alleles that are 
associated with psoriasis across different populations (Tazi Ahnini, Camp et al. 1999; 
Asumalahti, Laitinen et al. 2000; Enerback, Enlund et al. 2000; Enerback, Nilsson et al. 
2000; Asumalahti, Veal et al. 2002; Capon, Allen et al. 2004).  
HLA-C encodes a MHC class I protein involved in the presentation of intracellular 
antigens to CD8+ T lymphocytes (Falk, Rotzschke et al. 1993). CCHCR1 (alpha-Helix 
Coiled coil Rod homologue) encodes a ubiquitously expressed protein of unknown 
function, which is markedly up-regulated in psoriatic skin (Asumalahti, Laitinen et al. 
2000). Finally, CDSN encodes corneodesmosin, which is a structural protein involved in 
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keratinocyte adhesion and desquamation (Simon, Jonca et al. 2001).  
The strong LD conservation which characterizes the PSORS1 interval has long 
confounded the interpretation of these association data (Capon, Munro et al. 2002). 
However, the results of deep re-sequencing experiments (Nair, Stuart et al. 2006) and 
GWASs indicate that HLA-C is the most likely PSORS1 candidate gene (Nair, Duffin et 
al. 2009; Strange, Capon et al. 2010; Sun, Cheng et al. 2010). Of note, the HLA-
Cw*0602 allele has long been associated with psoriasis (Elder, Nair et al. 1994; Mallon, 
Bunce et al. 1997) but it is still unclear whether it represents the causal disease 























 Figure 1.5.3.1.1: Graphical representation of the PSORS1 locus 
The position of the MHC on chromosome 6p21 is shown in the upper panel. The 
position of known genes within the PSORS1 interval is shown in the lower part of the 
figure. The SEEK1, SPR1 and CDSN gene regions appear to overlap, as the three genes 
are transcribed from opposite DNA strands, on a common genomic segment. 












1.5.3.2 Non-MHC disease susceptibility loci  
Outside of the MHC, the results of genome-wide linkage scans have been inconclusive, 
reflecting the inadequacy of these studies for the analysis of loci with small phenotypic 
effects (International Psoriasis Genetics Consortium 2003). Conversely, the advent of 
GWASs has had a profound effect on our understanding of psoriasis genetics. In fact, 
the nine GWASs that have been carried out so far have allowed the identification of 23 
disease susceptibility loci (Table 1.5.3.2.1). It is interesting to observe that the majority 
of the genes identified in these studies can be linked to a small number of immune 
pathways. The most prominent is IL-23/IL-17/NF-țB axis, which plays a key role in the 
activation of Th17 lymphocytes (Di Cesare, Di Meglio et al. 2009).  
Large-scale genetic studies have also identified significant associations between 
psoriasis and CNVs from the ȕ-defensin and Late Cornified Envelope (LCE) gene 
clusters (Hollox, Huffmeier et al. 2008; de Cid, Riveira-Munoz et al. 2009). These 
findings indicate that the disruption of keratinocytes innate responses and barrier 
function also contribute to disease susceptibility. 
Of interest, a number of the psoriasis susceptibility variants identified in these studies 
have also been associated with other immune-mediated conditions (Table 1.5.3.2.2). 
This phenomenon, that is by no means unique to psoriasis, indicates the existence of 








Table 1.5.3.2.1: Loci associated with psoriasis susceptibility 
Gene* Chr. Protein 
function** 
Pathway References 




(Cargill, Schrodi et al. 
2007; Capon, Bijlmakers 
et al. 2008; Nair, Duffin et 
al. 2009; Ellinghaus, 
Ellinghaus et al. 2010; 
Strange, Capon et al. 
2010) 
IL28RA 1p36 Subunit of the 
IL-29 receptor
IFN signalling (Strange, Capon et al. 
2010) 





(de Cid, Riveira-Munoz et 
al. 2009; Zhang, Huang et 
al. 2009; Ellinghaus, 
Ellinghaus et al. 2010) 






(Strange, Capon et al. 
2010) 
IFIH1/ MDA5 2q24 Innate 
antiviral 
receptor 
IFN signalling (Strange, Capon et al. 
2010) 
ERAP1 5q15 Amino 
peptidase 
processing 




(Strange, Capon et al. 
2010; Sun, Cheng et al. 
2010) 
IL4, IL13 5q31 Cytokines 
produced by 
Th2 cells  
IL-4/IL-13 
signalling 
(Nair, Duffin et al. 2009) 
IL12B 5q33 Subunit 





(Cargill, Schrodi et al. 
2007; Nair, Duffin et al. 
2009; Zhang, Huang et al. 
2009; Ellinghaus, 
Ellinghaus et al. 2010) 
(Huffmeier, Uebe et al. 
2010)*** 








(Nair, Duffin et al. 2009; 
Strange, Capon et al. 2010; 
Sun, Cheng et al. 2010) 








(Sun, Cheng et al. 2010) 
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(Capon, Bijlmakers et al. 
2008; Nair, Duffin et al. 
2009; Zhang, Huang et al. 
2009; Ellinghaus, 
Ellinghaus et al. 2010; 
Strange, Capon et al. 
2010) (Huffmeier, Uebe et 
al. 2010)*** 







(Ellinghaus, Ellinghaus et 
al. 2010; Strange, Capon et 
al. 2010) (Huffmeier, Uebe 
et al. 2010)*** 







(Nair, Duffin et al. 2009; 
Strange, Capon et al. 
2010) 
CSMD1 8p23 Tumour 
suppressor 
gene 
Unknown (Sun, Cheng et al. 2010) 





(Nair, Duffin et al. 2009; 
Strange, Capon et al. 
2010) 






(Sun, Cheng et al. 2010) 





(Strange, Capon et al. 
2010; Stuart, Nair et al. 
2010) 






(Stuart, Nair et al. 2010) 
 





(Stuart, Nair et al. 2010) 
SERPINB8 18q21 Serine 
protease 
inhibitor 
Unknown (Sun, Cheng et al. 2010) 





IL-23 and IFN 
signalling  
(Strange, Capon et al. 
2010) 
ZNF816A 19q13 Zinc Finger 
Protein 





ZNF313/RNF114 20q13 E3 ubiquitin 
ligase  
IFN signalling (Capon, Bijlmakers et al. 
2008; Nair, Duffin et al. 
2009; Strange, Capon et al. 
2010; Stuart, Nair et al. 
2010) 
*Gene of interest found in the disease-associated susceptibility interval; **Function 





































IL23R 1p31 Crohn’s disease;  
Ankylosing 
spondylitis 
(Duerr, Taylor et al. 2006; Burton, 
Clayton et al. 2007) 




(Gregersen, Amos et al. 2009; 
Trynka, Zhernakova et al. 2009; 
Franke, McGovern et al. 2010) 
IFIH1 2q24 Type I diabetes (Smyth, Cooper et al. 2006; 
Nejentsev, Walker et al. 2009) 
ERAP1 5q15 Ankylosing 
spondylitis 
(Burton, Clayton et al. 2007) 
IL12B 5q33 
 
Crohn’s disease;  
Ulcerative colitis 
(Parkes, Barrett et al. 2007; Fisher, 
Tremelling et al. 2008) 
PTTG1 5q33 Systemic lupus  
erythematosus 
(Han, Zheng et al. 2009) 
TNIP1 5q33 
 
Systemic lupus  
erythematosus 
(Han, Zheng et al. 2009) (Gateva, 







Systemic lupus  
erythematosus; 
Celiac disease 
(Plenge, Cotsapas et al. 2007; 
Thomson, Barton et al. 2007; 
Graham, Cotsapas et al. 2008; 
Musone, Taylor et al. 2008; Trynka, 
Zhernakova et al. 2009) 





(Sigurdsson, Nordmark et al. 2005; 
Australia and New Zealand 
Multiple Sclerosis Genetics 
Consortium (ANZgene) 2009; 
Franke, McGovern et al. 2010; 


















1.6 Crohn’s disease 
1.6.1 Clinical presentation  
Crohn’s Disease (CD) is a subtype of Inflammatory Bowel Disease (IBD) (Table 
1.6.1.1), an idiopathic, chronic-relapsing condition occurring with a higher incidence in 
the Northern hemisphere (7 per 100,000 in the United States). CD can affect either sex, 
but an excess of female patients has been reported in all geographical regions (Mathew 
and Lewis 2004). Several factors can trigger the development of the disease, which 
usually occurs between the ages of 20 and 40. In fact, smoking, sedentary lifestyle and 
the alteration of the mucosal intestinal barrier are well recognised risk factors for CD. 
Although CD can affect any part of the GI tract, the terminal ileum and the ascending 
colon are the most frequent sites of inflammation. The distribution of lesions is 
characteristically patchy, with segments of normal tissue separating affected areas (Fig. 
1.6.1.1). 
The main symptoms of CD are abdominal pain and diarrhoea, leading to weight loss, 
tiredness, malabsorption and malnutrition. The GI tract inflammation can also result in 
bleeding, intestinal obstruction and fistulae formation. Of note, several studies have 
reported that patients affected by CD are at increased risk of developing other 
inflammatory diseases, such as primary sclerosing cholangitis, ankylosing spondylitis 
and psoriasis (Cho 2008). 
Different therapeutic approaches are available for the treatment of CD. These include 
the use of glucocorticoids, immunosuppressive drugs (e.g. azathioprine and 6-
mercaptopurine) and biologics (e.g. infliximab, a chimeric IgG-1 monoclonal antibody 
against TNF). Although these approaches can relieve disease symptoms, none of them 
can induce a permanent remission of the pathology. 
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Table 1.6.1.1: Contrasting features of the two forms of IBD 
Features Crohn’s Disease  Ulcerative colitis 
Location Any part of the GI tract Colon 
Lesion distribution Patchy  Continuous  






















Figure 1.6.1.1: Endoscopic image of CD 
An image of a CD patient inflamed bowel. Localized erythema with erosions and 
stricture of the lumen (blue arrow) are shown. 















1.6.2 Immunopathogenesis  
The disruption of GI barrier homeostasis is an early event in CD pathogenesis, which 
leads to an abnormal activation of innate and adaptive immune responses against 
resident microbiota. Thus, false recognition of commensal bacteria by DCs and 
intestinal epithelial cells results in macrophage and NK cell stimulation, as well as Th1 
and Th17 cell activation (Dharmani and Chadee 2008) (Fig. 1.6.2.1). The time of Th1 
and Th17 involvement is of particular interest. In fact, an experimental tri-nitrophenil 
(TNP)-colitis mouse model shows a bimodal distribution of cytokine release, 
characterized by an early Th1 phase, followed by a distinct Th17 response (Strober and 
Fuss 2011). In the final stages of disease pathogenesis, these lymphocyte populations 
migrate to the intestinal mucosa, where they stimulate macrophages to release the tissue 
damaging molecules (e.g. nitric oxide, free oxygen radicals and matrix metallo-
proteinases) that are responsible for the onset of CD symptoms (Dharmani and Chadee 





Figure 1.6.2.1: Overview of the events leading to the onset of CD 
In CD, inflammation is mediated by a crosstalk between cells of the innate and adaptive 
immune system. Activation of DCs by the gut microflora causes the polarization of 
naïve T lymphocytes into Th1 and Th17 cells, as well as the activation of Natural Killer 
cells and macrophages. The release of cytokines from these cells results in chronic 
epithelial inflammation. 





1.6.3 Genetics of Crohn’s disease  
The existence of a genetic component for CD is supported by repeated observations of 
higher concordance rates in monozygotic (40-60%) compared to dizygotic twins (0-
12%) (Podolsky 2002). On this basis, CD has long been considered as a complex 
disease, caused by gene-gene and gene-environment interactions. 
 
1.6.3.1 The NOD2/CARD15 susceptibility locus  
Genome-wide linkage scans carried out in the late 1990s led to the identification of 
NOD2/CARD15, as the first disease susceptibility gene for CD (Hugot, Chamaillard et 
al. 2001; Ogura, Bonen et al. 2001). NOD2 encodes a NOD-like receptor, which drives 
NF-NB mediated transcription, in response to the muramyl dipeptide constituent of 
bacterial cell walls (McDonald, Inohara et al. 2005). Approximately 30-50% of CD 
patients of European descent carry one of three NOD2 loss-of-function variants 
(R702W, G908R, L1007fsinsC). These alleles are associated with the strongest 
increases in disease risk observed for any CD gene, with heterozygous odds ratios 
ranging from 1.75 to 4 (Abraham and Cho 2009). 
 
1.6.3.2 Other Crohn’s disease susceptibility loci  
Linkage studies also identified disease susceptibility loci lying within the MHC (van 
Heel, Fisher et al. 2004) and the cytokine cluster on chromosome 5q31 (Rioux, Daly et 
al. 2001). The GWASs carried out in recent years have been considerably more 
successful, allowing the identification of more than 65 novel loci (Table 1.6.3.2.1). It is 
interesting to note that, similarly to what has been observed in psoriasis, many of the 
disease associated markers lie in genes that are related to IL-23/IL-17 and NF-țB 
signalling (Table 1.6.3.2.1). T cell activation and autophagy are among the other 
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pathways implicated by GWASs (Table 1.6.3.2.1). The latter observation is of 
considerable interest, given the well-document role of autophagy in innate and adaptive 
























Table 1.6.3.2.1: Loci associated with CD susceptibility 
Gene* Chr. Protein function** Cellular process References 
PTPN22 1p13 Protein tyrosine 
phosphatase  





McGovern et al. 
2010) 
IL23R 1p31 Subunit of the IL-23 
receptor 
IL-23 signalling (Duerr, Taylor 
et al. 2006; 
Franke, Hampe 
et al. 2007; 
Libioulle, Louis 
et al. 2007; 
Parkes, Barrett 
et al. 2007; 
Raelson, Little 
et al. 2007; 
Rioux, Xavier 





Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 








McGovern et al. 
2010) 
 





McGovern et al. 
2010) 
ITLN1 1q23 Lectin Glucose transport (Franke, 
McGovern et al. 
2010) 
None 1q24 - - (Barrett, 
Hansoul et al. 
2008; Franke, 








Endocytosis  (Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
KIF21B 1q32 Microtubule-binding 
protein 
Unknown (Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 




McGovern et al. 
2010) 
REL 2p16 Subunit of the NF-țB 
transcription factor 
NF-țB signalling (Franke, 
McGovern et al. 
2010) 
THADA 2p21 Unknown Unknown (Franke, 
McGovern et al. 
2010) 





McGovern et al. 
2010) 
GCKR 2p23 Glucokinase regulator Glucose transport (Franke, 
McGovern et al. 
2010) 
IL18RAP 2q12 Accessory subunit of 
the IL-18 receptor 
 
NF-țB and JNK 
signalling  
(Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010)  




McGovern et al. 
2010) 
ATG16L1 2q37 Part of a large protein 
complex required for 




Clayton et al. 
2007; Franke, 
Hampe et al. 
2007; Hampe, 
Franke et al. 
2007; Libioulle, 
Louis et al. 
2007; Parkes, 
Barrett et al. 
2007; Raelson, 
Little et al. 
2007; Rioux, 
Xavier et al. 
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2007; Barrett, 
Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
SP140 2q37 Nuclear body protein Unknown (Franke, 
McGovern et al. 
2010) 
MST1  3p21 Unknown Unknown (Barrett, 
Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010) 
PTGER4 5p13 Member of G protein 
receptor family 
T cell activation (Franke, Hampe 
et al. 2007; 
Libioulle, Louis 
et al. 2007; 
Raelson, Little 
et al. 2007; 
Rioux, Xavier 





Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
ERAP2 5q15 Amino peptidase 











Unknown (Franke, Hampe 
et al. 2007; 
Hampe, Franke 
et al. 2007; 
Barrett, 
Hansoul et al. 
2008; Franke, 










McGovern et al. 
2010) 
IRGM 5q33 Putative GTPase Autophagy (Parkes, Barrett 
et al. 2007; 
Raelson, Little 





Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010) 
IL12B 5q33 Subunit shared by the 
IL-12 and IL-23 
cytokines 
IL-23 signalling (Parkes, Barrett 
et al. 2007; 
Barrett, 
Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
CPEB4 5q35 Unknown Unknown (Franke, 
McGovern et al. 
2010) 





Fisher et al. 
2004; Franke, 
McGovern et al. 
2010) 





Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
BACH2 6q15 Transcription factor  MAFK signalling (Franke, 





PRDM1 6q21 Inhibitor of 
 beta-interferon gene 
expression 
B cell maturation (Franke, 
McGovern et al. 
2010) 
TAGAP 6q25 Putative Rho 
GTPase-activating 
protein 
T cell activation (Franke, 
McGovern et al. 
2010) 
CCR6 6q27 Chemokine receptor B cell maturation  (Barrett, 
Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
- 7p12 - - (Barrett, 
Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010) 





Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
TNFSF15 9q32 Cytokine NF-țB and 
MAPK signalling 
(Yamazaki, 






Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010) 
CARD9 9q34 Activates NF-NB via 
BCL10 
NF-țB signalling (Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
CREM 10p11 Transcriptional 
regulator binding the 
cAMP response 
element (CRE) 
cAMP signalling (Franke, 






IL2RA 10p15 Subunit of the IL-2 
receptor  





McGovern et al. 
2010) 
ZNF365 10q21 Unknown Unknown (Rioux, Xavier 





Hansoul et al. 
2008; Franke, 







McGovern et al. 
2010) 







McGovern et al. 
2010) 





Unknown (Parkes, Barrett 





Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
FADS1 11q12 Member of the fatty 
acid desaturase 
(FADS) gene family 
Lipid metabolism (Franke, 
McGovern et al. 
2010) 
C11orf30 11q13 Unknown Unknown (Barrett, 
Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 






PRDX5, ESRRA 11q13 PRDX5: member of 
the peroxiredoxin 










ESRRA: unknown  
(Franke, 





MUC19 12q12 Mucine  Epithelial cell 
protection 
(Franke, 
McGovern et al. 
2010) 
C13orf31 13q14 Unknown Unknown (Franke, 
McGovern et al. 
2010) 
TNFSF11 13q14 Cytokine  T cell 
proliferation 
(Franke, 
McGovern et al. 
2010) 
ZFP36L1 14q24 Unknown Unknown (Franke, 
McGovern et al. 
2010) 














McGovern et al. 
2010) 
SMAD3 15q22 Transcription factor TGF-ȕ signalling (Franke, 
McGovern et al. 
2010) 
IL27 16p11 Cytokine  T cell activation (Franke, 
McGovern et al. 
2010) 
NOD2/CARD15 16q12 NOD-like receptor NF-țB signalling (Hugot, 
Chamaillard et 
al. 2001; Ogura, 
Bonen et al. 
2001; Franke, 
Hampe et al. 
2007; Hampe, 
Franke et al. 
2007; Libioulle, 
Louis et al. 
2007; Parkes, 
Barrett et al. 
2007; Rioux, 







Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010) 
CCL2/CCL7 17q12 Chemokines JAK/STAT 
signalling 
(Franke, 
McGovern et al. 
2010; 
McGovern, 










Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 







Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
PTPN2 18p11 Protein tyrosine 
phosphatase  
IFN signalling (Parkes, Barrett 





Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 














Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
TYK2  19p13 Tyrosine kinase 
associated with 
cytokine receptors 
IL-23 and IFN 
signalling 
(Franke, 
McGovern et al. 
2010) 
FUT2 19q13 Fucosyl-transferase Blood antigen 
biosynthesis 
(Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
TNFRSF6B  20q13 Member of the tumour 
necrosis factor 
receptor superfamily 
Apoptosis  (Franke, 
McGovern et al. 
2010) 
ICOSLG 21q22 Ligand for the T cell 
surface receptor ICOS
T cell activation (Barrett, 
Hansoul et al. 
2008; Franke, 
McGovern et al. 
2010) 
YDJC 22q11 Unknown Unknown (Franke, 
McGovern et al. 
2010) 
MTMR3 22q12 Lipid and protein 
phosphatase 
Autophagy (Franke, 
McGovern et al. 
2010) 
MAP3K7IP1 22q13 MAP kinase regulator TGF-ȕ signalling (Franke, 
McGovern et al. 
2010; 
McGovern, 
Jones et al. 
2010) 
*Gene of interest found in the disease-associated susceptibility interval; **Function 
annotated in the Uniprot protein database. 











1.7 Aim and overview of the project 
The hypothesis driving this study is that CD susceptibility genes may contribute to the 
pathogenesis of psoriasis by affecting shared inflammatory pathways. This notion is 
supported by the results of early GWASs, which demonstrated the existence of 
pleiotropic susceptibility genes predisposing to the onset of clinically distinct disorders 
(The Wellcome Trust Case-Control Consortium 2007). More recently, psoriasis and CD 
GWASs have identified IL23R and IL12B as genes conferring susceptibility to both 
conditions (Duerr, Taylor et al. 2006; Capon, Di Meglio et al. 2007; Cargill, Schrodi et 
al. 2007; Barrett, Hansoul et al. 2008). Of note, both IL12B and IL23R are involved in 
the processes leading to the activation of Th17 lymphocytes (Di Cesare, Di Meglio et al. 
2009), a T cell subset that plays a key role in the pathogenesis of chronic inflammation 
(Martinez, Nurieva et al. 2008). 
To address the hypothesis that further CD variants may be associated with psoriasis 
susceptibility, 26 CD loci identified prior to the onset of this study were examined in a 
well characterized clinical resource, including 1,256 psoriatic patients and 2,938 
unrelated controls. Positive findings were followed-up in an independently ascertained 
dataset, including 1,348 cases and 1,368 controls. These analyses identified an 
association between psoriasis and a SNP lying within the CDKAL1 gene.  
To better characterize the function of CDKAL1, the gene expression pattern was 
analysed in multiple tissues and cell types. Stable CDKAL1 knock-down cell lines were 
also generated and characterized by a variety of methods, including cell cycle analysis 
and transcriptome profiling. The results of these experiments indicated that CDKAL1 





Chapter 2: Materials and methods 
2.1 Materials  
 


























Cascade Biologics  
 
Cy-3-Streptavidin GE Healthcare 
 














































































































































sh-RNA-V2LHS_17373 individual clone 
 
Open Biosystems 

























TaqMan Gene expression assays 
 
Applied Biosystems  
 
TaqMan Genotyping master mix  
 
Applied Biosystems 






























10X ligase buffer 
 
New England Biolabs 
 
10X NEBuffer 4 
 
New England Biolabs 
 
10X PCR buffer 
 
New England Biolabs 
 
Calf Intestinal alkaline phosphatase (CIP) 
 


















T4 DNA ligase 
 












New England Biolabs 
 
 60








































































































































































Goat Anti-Rabbit IgG _HRP 
 










Į- ȕ actin 
 

































































































1X Tris-EDTA buffer (TE)  
 




10X Running buffer 
 
 
250 mM Tris base 
 
1.92 M Glycine 
 
1% (w/v) SDS 
 
10X Tris-Borate-EDTA buffer (TBE) 
 
90 mM Tris base 
 
90 mM Boric acid 
 
1 mM EDTA 
 
Coomassie blue stain solution  
 
 
0.5% (w/v) Coomassie blue 
 
40% (v/v) Methanol 
 
Chorionic Villus Sample buffer (CVS) 
 
 
10 mM Tris base 
 
1 mM EDTA 
 
0.1 M NaCl 
 
0.5% (v/v) SDS 
 
Adjust pH to 10.5 with NaOH 
 




10 mM HEPES pH 7.9 
 
10 mM KCl 
 
0.1 mM EDTA 
 
0.1 mM EGTA 
 





40% (v/v) MeOH 
 
10% (v/v) NaOAc 
 
Luria broth (LB)/agar (LUA) 
 
1% (w/v) Bacto-Tryptone 
 
1% (w/v) NaCl 
 
0.5% (w/v) Yeast extract 
 
For LUA, add 1.5 % (w/v) Bacto-Agar
 




20 mM HEPES pH 7.9 
 
0.4 M NaCl 
 
1 mM EDTA 
 
1 mM EGTA 
 





0.1% (w/v) Ponceau S 
 
5% (v/v) Glacial acetic acid 
 





120 mM NaOAc, pH 4.6 
 
Sucrose lysis buffer 
 
0.3 M Sucrose 
 
10 mM Tris-HCl, pH 7.5 
 
5 mM MgCl2 
 
1% Triton X-100 
 
Total cell extract buffer 
 





Transfer buffer  
 
25 mM Tris base 
 
192 mM Glycine 
 
20% (v/v) MeOH (add immediately 
before use) 
 
Transformation buffer (TB) 
 
 
15 mM CaCl2 
 
250 mM KCl 
 
10 mM PIPES 
 
55 mM MnCl2 
 
10X Tris Buffered Saline (TBS) 
 
1.5 M NaCl 
 


















2.2 Subjects  
2.2.1 Study subjects  
A total of 1,256 British patients of North European descent were enrolled in this study. 
All cases were ascertained from specialist dermatology clinics, at St John’s Institute of 
Dermatology, London (n= 638), Glasgow Western Infirmary (n= 211), and the 
Dermatology Centre, University of Manchester (n= 407). Experienced dermatologists 
from each institution confirmed that all patients showed early onset (occurring before 40 
years of age) psoriasis vulgaris, defined according to established clinical criteria (Camp 
1998). Less than 1% of the patients were also known to suffer from CD.  
The control individuals (n= 2,938) had been previously analysed by the Wellcome Trust 
Case-Control Consortium (WTCCC) and originated from two sources, the 1958 British 
Birth Cohort and the UK Blood Service (The Wellcome Trust Case-Control Consortium 
2007) . 
A total of 1,348 cases and 1,368 unrelated controls from the Collaborative Association 
Study of Psoriasis (CASP) were used as a replication dataset. Both cases and controls 
were recruited in the US among individuals of North-European descent (Nair, Duffin et 
al. 2009). Human studies were conducted in accordance with the Helsinki Declaration 
and approved by the Ethics Committees of all participating institutions. All cases and 
controls gave their informed consent for the use of their DNA in genetic epidemiology 
analyses.  
 
2.2.2 DNA extraction from peripheral blood  
Genomic DNA was extracted from peripheral blood leukocytes using the “salting out” 
method (Miller, Dykes et al. 1988). Ten milliliters of blood were collected in EDTA 
containers, dispensed in 50 mL polypropylene tubes and mixed with 40 mL of ice-cold 
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distilled water (dH2O). Samples were centrifuged at 3,000 rpm for 10 min at 4C. The 
supernatant was discarded and the pellet re-suspended in 25 mL of ice-cold sucrose lysis 
buffer. Samples were again centrifuged at 3,000 rpm for 10 min at 4C. The supernatant 
was discarded and the pellet re-suspended in 3 mL CVS buffer supplemented with 25 
µL of 20 mg/mL proteinase K. Samples were incubated at 60C for 2-3 hours or 
overnight at 37C and then vortexed to ensure that the pellet was completely dissolved. 
Subsequently, 1.8 mL of 5 M NaCl was added to the solution and tubes were 
centrifuged at 3,500 rpm  for 30 min at 4C. The supernatant was transferred to clean 15 
mL polypropylene tubes and DNA was precipitated by adding 5 mL 90% ethanol. DNA 
was transferred into 1.5 mL tubes containing 1 mL 70% ethanol and centrifuged at 
3,000 rpm  for 10 min. After discarding the supernatant the pellet was resuspended in 1 
mL of TE pH8.0. 
 
2.2.3 DNA plating  
DNA samples were quantified by measurement of their OD260 with a NanoDrop 
ND1000 Spectrophotometer (Labtech). DNAs were aliquoted into 96 well plates at a 
concentration of 25 ng/ȝL. Positive (two duplicate samples in each plate) and negative 
controls were also plated, in order to verify the reproducibility of genotyping results and 
to detect the presence of cross-contamination. 
 
2.3 DNA typing  
2.3.1 Single Nucleotide Polymorphism genotyping  
Patient DNAs were typed using TaqMan SNP Genotyping Assays. These reagents allow 
accurate genotypic discrimination based on the use of allele-specific fluorochromes 
(VIC for allele 1 and FAM for allele 2) linked to the 5’ end of two oligonucleotide 
 69
probes. Each TaqMan probe also contains a minor groove binder (MGB) at the 3’ end 
(allowing the user to increase the melting temperature and to design shorter probes) and 
a quencher that acts by decreasing background fluorescence. Allele specific signals are 
detected when the probes are incorporated into the PCR product and the quencher is 
cleaved. 
All genotyping reactions were performed in 96 well plates covered by optical adhesive 
lids. A master mix was prepared to a final volume of 260 µL, including 130 µL 2X 
TaqMan Genotyping master mix, 6.5 µL TaqMan Genotyping Assay and 123.5 µL 
dH2O. 2.5 µL of master mix were dispensed in each well and 1 µL of DNA (25 ng/µL) 
was added. PCR reactions were carried out in a BIORAD PTC-100 Peltier thermal 
cycler, under the following conditions: 15 min 95°C; (15 sec 92°C, 1 min 60°C) x 44. 
Amplification products were visualized on an Applied Biosystems Real-time PCR 
7900HT apparatus, using the SDS 2.2 software . 
 
2.3.2 Direct sequencing  
2.3.2.1 Primer design  
Primers amplifying the regions of interest (Table 2.3.2.1.1) were designed using the 
















CDKAL1 full-length cDNA 5’-TGCAGATTTATGGCTCCTGA-3` 
5’- AGCAAAAAGAAGACCCAGCA-3` 





















2.3.2.2 Polymerase Chain Reaction (PCR) 
PCR reactions were carried out in a 20 µL final volume in the presence of 0.25 µM 
forward and reverse oligonucleotide primers, 1X Taq PCR reaction buffer (75 mM Tris-
HCl (pH8.8), 20 mM NH4SO4, 1.5 mM MgCl2, 0.01% (v/v) Tween-20), 0.2 mM dNTPs, 
and 0.05 U/µL Taq polymerase. The amplification reaction was carried out in a 
BIORAD PTC-100 thermal cycler under the following conditions: 96C for 2 min 
(96°C 30 sec; 55°C 30 sec; 72°C 30 sec) x 30; 72°C 5 min. Three microlitres of PCR 
product plus 3 µL of 5X loading dye were loaded on a 2% agarose gel containing 0.5 
µg/mL ethidium bromide, alongside the HyperLadder I DNA sizing marker. Gels were 
electrophoresed at 130 V in 1X TBE buffer and PCR products were visualized on an UV 
transilluminator. 
 
2.3.2.3 Direct sequencing  
Sequencing reactions were performed in 96 well plates. PCR products were purified 
using the ExoSAP-IT reagent, a mixture of exonuclease and shrimp alkaline 
phosphatase that removes the excess of primers and nucleotides used in the 
amplification reaction. Two microlitres of PCR product were mixed with 3 µL of 
ExoSAP-IT and incubated at 37°C for 30 min, followed by an additional 15 min at 
80°C. Amplicons were sequenced with 2 ȝM primer (Table 2.3.2.1.1), using 1.25 µL of 
5X buffer and 0.25 µL BigDye 3.1 reagent. After 30 sequencing cycles (96°C 30 sec; 
50°C 15 sec; 60°C 60 sec), reactions were purified by ethanol precipitation. Briefly, 26 
µL of precipitation solution was added to each reaction. Samples were incubated at 
room temperature for 10 min and centrifuged at 3,000 rpm for 30 min. The supernatant 
was removed by a brief centrifugation of the inverted plate at 400 rpm. Samples were 
washed with 70 µL of 70% ethanol and further centrifuged at 3000 rpm for 10 min. 
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Ethanol was removed and the pellet was air-dried for 10 min, re-suspended in 10 µL of 
HiDi formamide and denatured at 90C for 2 min. Samples were loaded on an ABI 
3730xl sequencer (Applied Biosystems). Sequence analysis was conducted by visual 
inspection of chromatograms, using both the FinchTV (available at 
www.geospiza.com/finchtv.html) and the Sequencher 4.7 
(http://www.softpedia.com/get/Science-AD/Sequencher.shtmlprograms) software.  
 
2.4 Cell culture 
2.4.1 Culture conditions 
2.4.1.1 Adherent immortalized cell lines  
All tissue culture procedures were performed under sterile conditions using a laminar 
flow hood (NUAIRE, Biological Safety Cabinet). In-vitro spontaneously transformed 
keratinocytes from histologically normal skin (HaCaT) and Human Embryonic Kidney 
293 cells (HEK293T) cells were grown in a humidified atmosphere at 37C in 5% CO2. 
Both cell lines were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) 
supplemented with 10% Fetal Calf Serum (FCS), 2 mM L-glutamine, 100 U/mL 
penicillin and 100 µg/mL streptomycin (complete medium). For cryopreservation, 
aliquots of 106 cells were prepared in a final volume of 1 mL 90% FCS/10% Dimethyl 
Sulphoxide (DMSO) and transferred to liquid nitrogen, after a progressive temperature 
shift. 
Cells were passaged upon reaching 80% confluence. The medium was removed and the 
cells washed in Phosphate Buffered Saline (PBS) in order to remove any trace of serum. 
Cells were incubated at 37C for 5 min, in 2.5 mL of pre-warmed trypsin-EDTA. The 
trypsin was inactivated by adding 5 mL fresh complete medium into the flask. Cells 
were centrifuged at room temperature for 5 min at 1,200 rpm and the pellet resuspended 
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in 10 mL of fresh medium.  
 
2.4.1.2 Cell lines grown in suspension  
Jurkat immortalized T cells were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin 
and 100 µg/mL streptomycin (complete medium). Cells were cryopreserved for storage 
as described above and were maintained at a concentration of 3-9 x 104 cells/mL. When 
this density was exceeded, cells were centrifuged at room temperature at 1,200 rpm for 
5 min. The pellet was washed in PBS and resuspended in 10 mL fresh medium. 
 
2.4.1.3 Primary keratinocytes 
Primary keratinocytes were derived from the skin biopsies of three consenting donors 
(two unaffected individuals and a psoriatic patient). The dermis was cleaned of fat using 
a scalpel; the skin was cut in small stripes, transferred in a 6 well plate and incubated 
overnight on a shaker with 5 mg/mL dispase. The epidermis was separated from the 
dermis with sterile forceps and washed in 4 mL of sterile PBS. The epidermis was then 
incubated with 4 mL trypsin-EDTA at 37 C for 15 min. The tissue was homogenised 
using a 5 mL syringe and immediately passed through a 100 ȝm cell mesh (BD 
Bioscience) pre-treated with FCS. The cell suspension was transferred to a 10 mL tube 
and washed in PBS twice. The pellet was re-suspended in 10 mL Epilife keratinocyte 
medium supplemented with Human Keratinocyte Growth Supplement and transferred to 
75 cm2 flasks pre-coated with coating matrix. Keratinocytes were maintained in culture 
until a confluent monolayer was formed. Cells were trypsinised as described above and 
cytokine treatment was carried out between passages 2-4. Cells were quiesced by 
culturing them in supplement-free medium for 24 hours. Based on published data on the 
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kinetics of cytokine induced gene expression (Hundhausen, Bertoni et al. 2011), 
keratinocytes were incubated with 100 ng/mL of the relevant cytokine (either IL-17, IL-
22, IL-23, IFN-Į, IFN-Ȗ or TNF-D) for 24 hours (5 hours for IFN-Į). All treatments 
were carried out in duplicate.  
 
2.4.2 Immunofluorescence staining  
HaCaT cells were cultured on coverslips in a 20 mm culture dish. After reaching 40% 
confluence the cells were washed twice in PBS and then fixed in 4% paraformaldehyde 
(pH>7) for 5 min. After an additional PBS wash, the cell membranes were 
permeabilized in 0.6% H2O2, 0.1% Triton X-100 for 10 min at room temperature. Fixed 
cells were blocked for 20 min at room temperature in a PBS buffer containing 0.1% 
BSA, 10% goat serum, and 0.1% Tween20. Cells were incubated with a primary D-
CDKAL1 antibody, at a final concentration of 1µg/mL for 1.5 hours at room 
temperature. Following two washes in PBS, a secondary antibody (Alexa Fluor 555 
goat anti-mouse IgG (H+L) F (Ab) 2 fragments) was added at a dilution of 1:200 in 
blocking buffer. After 30 min incubation at room temperature, coverslips were mounted 
onto optical slides with Prolong Gold AntiFade Reagent supplemented with 4’,6-
diamidino-2-phenylindole (DAPI). Images were acquired using a fluorescence 
microscope (Zeiss Axiophot) and analysed with the NIS-Elements BR 3.0 software. 
 
2.5 Cell transfection and transduction 
2.5.1 Transient CDKAL1 RNA interference 
HaCaT cells from a confluent culture were counted under an optical microscope 
(ZEISS) using a haemocytometer. Thirty-five thousand cells were plated into each well 
of a 24 well plate and grown overnight in complete DMEM. A 33 nM pool of four 
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RNAi oligonucleotides (ON-TARGETplus SMARTpool siRNA), was incubated in 50 
µL serum-free DMEM for 5 min at room temperature. The diluted oligonucleotides 
were combined with 1 µL Lipofectamine 2000 and incubated at room temperature for 
an additional 20 min. The oligonucelotide-Lipofectamine complex was added to the 
medium of each well and mixed by gentle swirling. The medium was replaced with 
complete DMEM after 24 hours and cells were grown for a further 48-72 hours.  
 
2.5.2 Stable CDKAL1 RNA interference  
2.5.2.1 Lentivirus production  
All lentivirus work was performed in level 2 containment facilities. HEK293T cells, 
grown in 100 mm cell culture dishes, were transfected with 6 µg HIV-gag/pol 
expressing vector, 1.5 µg VSV-G expressing vector (both obtained from the Addgene 
plasmid repository, accessible at http://www.addgene.org/pgvec1), 6 µg of the relevant 
sh-RNA construct (either sh-non-silencing, sh-RNA-V2LHS_173734 individual clone 
or sh-RNA-V2LHS_17373 individual clone). Plasmids were diluted in 750 µL serum 
free medium and incubated at room temperature for 5 min. Sixty microlitres of 1 mg/mL 
polyethylenimine (PEI) were added and the mixture was incubated for an additional 20 
min at room temperature. The complex was added to the cell medium and mixed by 
gentle swirling. After 24 hours the medium was replaced with 8 mL complete DMEM. 
After a further 48-72 hours the medium was collected, centrifuged at 1,500 rpm for 5 
min at room temperature and stored at -80C. 
 
2.5.2.2 Cell transduction  
Four millilitres of supernatant from transfected HEK293T cells was diluted in 4 mL of 
complete medium supplemented with 8µg/mL Sequa-brene, and mixed with 2 x 106 
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HaCaT or 4 x 106 Jurkat cells. The efficiency of transduction was assessed after 24 
hours, by using fluorescence microscopy (see below) to identify the cells expressing 
tGFP. After a further 24 hours, cells were placed under antibiotic selection, by 
supplementing the medium with 15 µg/mL puromycin. The selection medium was 
replaced every 72 hours until puromycin resistant colonies appeared.  
 
2.5.2.3 HaCaT cell clonal expansion  
One hundred transduced HaCaT cells were cultured in 20 mm cell culture dishes for 1 
week. Well defined clones arising from individual cells were then highlighted with a 
marker under the microscope. The medium was removed and cells washed twice in 
PBS. A sterile cloning ring was placed around the marked colonies, using sterile 
Vaseline to seal it. Two hundred microlitres of pre-warmed trypsin-EDTA was added to 
the ring and cells were incubated at 37C for 5 min. The trypsin-EDTA and cell 
suspension was added to 5 mL of complete DMEM and centrifuged at 1,200 rpm at 
room temperature for 5 min. The cell pellet was resuspended in 500 µL compete 
DMEM and cells were plated in 6 well plates. 
 
2.5.2.4 Jurkat T cell clonal expansion 
The clonal expansion of transduced Jurkat T cells was performed in 96 well plates by 
growing a limiting cell dilution (0.5 cells per well) in the presence of previously 
irradiated at 50 Gy untransduced Jurkat cells as feeders. Cells were incubated at 37C in 
5% CO2 in RPMI 1640 medium supplemented with 2.5 µg/mL Pytohemagglutinin-M 
(PHA). After a week the medium was replaced with complete RPMI supplemented with 
20 IU/mL interleukin-2 (IL-2). Cells were cultured until the appearance of clusters 
indicated they had reached an appropriate density for expansion. 
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2.6 Cell cycle analysis 
2.6.1 WST-8 proliferation assay 
This colorimetric cell viability assay is based on the cleavage of the WST-8 tetrazolium 
salt into formazan. As this reaction is catalyzed by a mitochondrial dehydrogenase that 
is more active during cell proliferation, the accumulation of formazan directly correlates 
with the number of metabolically active cells. 
Thirty thousand transduced HaCaT cells, were seeded in triplicate in a 24 well plate and 
grown in 500 ȝL complete DMEM. After 24 hours the medium was replaced with 500 
ȝL reduced (1.5%) FCS DMEM and cells were grown for a further 24 hours. The 
medium was replaced with 500 µL complete DMEM and cells incubated for an 
additional 24 hours, after which 50 ȝL of WST-8 were carefully added. The 
accumulation of formazan was monitored by measuring its absorbance (450 nm) every 
30 min on a Fluorostar Omega plate reader (Labtech). 
 
2.6.2 Propidium iodide staining 
Propidium iodide (PI) is a fluorescent DNA intercalating agent that is used to identify 
the proportion of cells in that are in the G0/ G1, S or G2/M phase of the cell cycle. 
One million transduced HaCaT cells were washed twice in 1 mL PBS. The pellet was 
fixed in 1 mL ice-cold 70% ethanol and incubated at 4 °C overnight. Fixed cells were 
washed twice in PBS and the pellet treated with 50 ȝg RNase and 20 ȝg PI, in a final 
volume of 500 ȝL. Cells were incubated at room temperature in the dark for 30 min and 
subsequently analyzed by flow cytometry, using a FACScanto apparatus (BD). Data 




2.7 Plasmid DNA cloning 
2.7.1 Preparation of DH5Į competent cells 
E.coli DH5Į cells were streaked on a Luria broth agar plate (LUA) and incubated at 
37°C overnight. One representative colony was inoculated in 2 mL LB medium and 
grown at 37°C overnight shaking at 160 rpm. One millilitre of culture was added to 500 
mL LB medium supplemented with 2 M MgCl2 and incubated at 18°C, until OD600 
reached 0.3. The culture was rapidly cooled on ice and cells were centrifuged at 3,000 
rpm for 10 min, at 4°C. The cell pellet was resuspended in 150 mL ice cold 
Transformation Buffer (TB). Cells were further centrifuged at 3,000 rpm for 10 min at 
4°C and the pellet was resuspended in 40 mL cold TB. Three millilitres of DMSO were 
added with gentle swirling. Five-hundred microlitres of cell suspension was aliquoted 
into 1.5 mL tubes and immediately chilled in liquid nitrogen. Cells were stored at -80 
°C. 
 
2.7.2 Digestion  
Following an analysis of CDKAL1 full-length cDNA sequence (accession n.: 
NM_017774) with NEB cutter v2.0 (http://tools.neb.com/NEBcutter2/index.php), 
EcoRI and XhoI were selected as suitable enzymes for the cloning procedure. 
Accordingly, EcoRI- and XhoI- tagged PCR primers were designed (Table 2.3.2.1.1). 
The full length CDKAL1 transcript was amplified from Image clone 30379056, using a 
10:1 mix of Taq/Pfu polymerase (all other reagents were as described in section 2.3.2.2). 
An initial denaturation step (96C for 2 min) was followed by 30 amplification cycles 
(96°C 30 sec; 55°C 30 sec; 72°C 1 min) and a final extension (72°C 5 min). The PCR 
product was column-purified using the QIAquick PCR purification kit according to the 
manufacturer’s protocol. Digestion of PCR product and pGEX-4T-1 vector was carried 
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out in a final volume of 20 µL, as detailed in table 2.7.2.1. The reaction was incubated 
at 37C for 2 hours. After 1.5 hours 10 IU of Calf Intestinal alkaline Phosphatase (CIP) 
were added to the vector, in order to prevent its re-circularisation. Digestion products 
were quantified by visualisation on an agarose gel alongside a Hyperladder I molecular 
weight marker (see section 2.3.2.2). 
 
 80
Table 2.7.2.1: DNA restriction 
    Components Volume (insert) Volume (vector) 








   2 µL 
 
   2 µL 
 
  0.5 µL 
 
  0.5 µL 
  6 ȝL (800 ng) 
  - 
  9 ȝL 
  20 ȝL 
   2 µL 
 
   2 µL 
 
  0.5 µL 
 
  0.5 µL 
  -    
  4 ȝL (1 ȝg)  
  11 ȝL 

















2.7.3 DNA ligation and bacterial transformation 
Fifty nanograms of digested pGEX-4T-1 vector were combined with 72 ng of CDKAL1 
RT-PCR product (3:1 insert: vector molar ratio), in a 20 µL ligation reaction containing 
2 µL 10X ligase buffer and 1U of T4 DNA ligase. Samples were incubated at 15C 
overnight. 
Ligation products were transformed into competent E.coli DH5Į cells as follows. One-
hundred microlitres E.coli DH5Į cells were slowly defrosted and incubated with the 
ligation product for 30 min on ice. Cells were heat-shocked at 42C, for 90 sec and 
cooled on ice for a further 2 min. Five-hundred microlitres of LB medium were added 
to the suspension, and incubated for 1 hour at 37C. Samples were centrifuged at 9,000 
rpm, for 5 min. The bacterial pellet was resuspended in 100 µL of LB medium and 
plated onto selective LUA plates containing 50 µg/mL ampicillin. After an overnight 
incubation at 37C, individual colonies were inoculated in 5 mL LB medium 
supplemented with 50 µg/mL ampicillin. Cultures were incubated at 37°C overnight, 
with shaking at 160 rpm. Glycerol stocks were prepared by mixing 750 µL of overnight 
cultures with 250 µL 80% glycerol. 
 
2.7.4 Colony screening 
The overnight cultures described above were screened by PCR, in order to confirm the 
presence of the desired insert. All reactions were carried out in a final volume of 50 µL. 
Briefly, 2 µL of overnight culture were incubated with 1 µL of Tween 20 and 34.85 µL 
of dH2O for 10 min at 95C. A master mix containing 5 µL of 1X Taq PCR reaction 
buffer, 5 µL of 0.2 mM dNTPs, 1 µL of 0.2 µM CDKAL1 forward and CDKAL1 reverse 
primers and 0.15 IU/µL Taq polymerase was added to the mixture. Samples were 
amplified under the conditions described in section 2.7.2. Amplification products were 
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visualized by agarose gel electrophoresis. 
 
2.7.5 Plasmid DNA extraction 
Overnight cultures were centrifuged for 5 min at 4,600 rpm at 4C. Plasmid DNA was 
extracted using QIAprep Miniprep or QIAprep Maxiprep kits according to the 
manufacturer’s protocol. The concentration of plasmid DNA was quantified with a 
Nanodrop ND-1000 spectrophotometer. Plasmids were sequenced as described above, 
in order to verify the integrity and orientation of the insert. 
 
2.8 Transcript analysis 
2.8.1 RNA extraction 
Total RNA was isolated from cultured cells, using either the RNeasy Plus Mini Kit or 
TRI REAGENT, according to the manufacturer’s protocol. The RNA yield was 
determined by quantifying the samples on a Nanodrop ND1000 UV-vis 
Spectrophotometer . The concentration of the RNA samples to be used in the microarray 
experiment was further confirmed by Quanti-iT RNA assay using a Qubit fluorometer 
(Invitrogen). The quality of these RNAs was also assessed by using a Bioanalyzer 2100 
(Agilent) to monitor the presence of degradation products within the sample. 
 
2.8.2 cDNA and cRNA synthesis  
cDNA was synthesised from 500 ng total RNA, using the QuantiTect Rev. Transcription 
Kit. cRNA was transcribed from 500 ng total RNA, using Illumina’s TotalPrep RNA 




2.8.3 Hybridisation of gene expression chips 
Samples were hybridised to a HumanHT-12_v3_BeadChip (Illumina), using Illuminas’s 
Whole-Genome Gene Expression Direct Hybridization Assay Kit, according to the 
manufacturer’s instructions. 
 
2.8.4 Qualitative Reverse Transcription (RT)-PCR 
Two microlitres of cDNA were amplified in a in a 20 µL final volume (see section 
2.3.2.2 for a list of reaction components and Table 2.3.2.1.1 for primer sequences). An 
initial denaturation step (96C for 2 min) was followed by 38 amplification cycles (96°C 
30 sec; 55°C 30 sec; 72°C 30 sec) and a final extension (72°C 5 min). Three microlitres 
of PCR product were loaded on agarose gel and visualized as described in section 
2.3.2.2  
 
2.8.5 Quantitative RT-PCR 
Gene expression was assessed by singleplex real-time quantitative RT-PCR using 
Taqman Gene Expression Assays according to the manufacturer’s instructions. All PCR 
reactions were carried out in duplicate in 96 well plates covered by optical adhesive 
lids. Samples were amplified in an Applied Biosystems 7900HT Sequence Detection 
System, under the following conditions: 15 min 95°C; (30s 95°C, 1 min 60°C) x 40. 
The relative CDKAL1 expression levels were analyzed using the ǻǻCt method as 
described in section 2.11.3. 
 
2.9 Protein analysis 
2.9.1 Total cell lysis of adherent cells 
Cells were cultured in 24 well plates in complete DMEM, until they reached 80-90% 
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confluence. Cells were washed in PBS and treated with 150 µL of ice cold lysis buffer, 
supplemented with a cocktail of protease inhibitors (Complete, Mini, EDTA-free 
tablets). The plate was incubated for 20 min at 4C with gentle shaking. Next, the cells 
were scraped and transferred to a micro-centrifuge tube. The lysate was clarified by 
centrifuging samples for 10 min at 4,600 rpm, at 4C. The supernatant was transferred 
to a new micro-centrifuge tube and stored at -80C. 
 
2.9.2 Total cell lysis of suspension cells 
Three million cells were centrifuged 1,200 rpm at room temperature, for 5 min. The 
supernatant was removed and the pellet was washed in 5 mL ice-cold PBS. Following 
an additional centrifugation, the pellet was resuspended in 300 µL ice cold cell lysis 
buffer supplemented with protease inhibitors. Cells were incubated for 30 min on ice 
and briefly vortexed. The supernatant was transferred to a micro-centrifuge tube and 
centrifuged for 10 min at 4,600 rpm, at 4C. The supernatant was transferred to a fresh 
tube and stored at -80C. 
 
2.9.3 Nuclear and cytoplasmic protein extraction 
The pellet from 3 x 106 adherent or 5 x 106 suspension cells was re-suspended in 400 µL 
ice cold cytoplasmic lysis buffer and left on ice for 15 min. Cells were supplemented 
with 10% NP40, vortexed vigorously for 20 sec, incubated on ice for 20 min and finally 
centrifuged at 4,600 rpm for 10 min at 4C. The supernatant was collected without 
disturbing the nuclear pellet, transferred to a new 1.5 mL pre-chilled tube and stored at -
80C. The nuclear pellet was washed several times in cytoplasmic lysis buffer and 
centrifuged at 1,600 rpm at 4C for 10 min. The nuclear pellet was resuspended in 400 
µL ice cold nuclear cell lysis buffer and incubated at 4C overnight, in a shaker. The 
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suspension was centrifuged at 1,600 rpm at 4C for 20 min. The supernatant was 
transferred to a pre-chilled 1.5 mL tube and stored at -80C. 
 
2.9.4 Protein quantification 
All protein extracts were quantified using the Bicinchoninic Acid Protein Assay (BCA) 
kit. The assay is based on the reduction of the Cu2+-protein complex into Cu1+, which, 
under alkaline conditions results in the formation of a purple-blue complex (Smith, 
Krohn et al. 1985). Samples were treated according to the manufacturer’s protocol and 
the colorimetric reaction was quantified on a Fluorostar Omega plate reader at 562 nm.  
 
2.9.5 Western blotting 
Twenty micrograms of protein extract were mixed with gel loading buffer at a 1:1 ratio. 
Samples were denatured at 90C for 5 min, chilled on ice and electrophoresed in a 10% 
discontinuous SDS-polyacrylamide minigel (see Tables 2.9.5.1 and 2.9.5.2), in the 
presence of 7 µL protein sizing ladder. Proteins were separated at 120V for 2 hours and 
subsequently transferred onto a Protran Nitrocellulose membrane, using the Trans-blot 
SD Semi-dry Transfer cell blotting system (BIORAD), at 250 mA for 40 min. Transfer 
efficiency was checked by Ponceau red staining of proteins and membranes were 
blocked for 2 hours in 5% skimmed milk diluted in 0.1% Tween 20_Tris Buffered 
Saline (TBS). The membranes were incubated overnight at 4C with the relevant 
antibody, washed 4 times in TBS-0.1% Tween 20 and incubated for 2 hours at room 
temperature with the relevant HRP-conjugated secondary antibody (see Table 2.9.5.3). 
After a second round of washing, membranes were stained for 5 min at room 
temperature with ECLplus. Protein bands were detected by autoradiography. 
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Table 2.9.5.1: Separating gel components  
Components 10% gel 8% gel 
H2O  
Ultra Pure ProtoGel 30% acrylamide mix  
1.5M Tris (pH8.8) 
10% SDS 

























Table 2.9.5.2: 5% Stacking gel components 
Components Volumes 
H2O  
Ultra Pure ProtoGel 30% acrylamide mix  
1.5M Tris (pH6.8) 
10% SDS 



















Table 2.9.5.3: Antibodies used in western blot experiments 
Primary antibodies Dilutions Secondary antibodies Dilutions 
Į-CDKAL1 
Į- ȕ actin 





Goat Anti-Rabbit IgG HRP 
 
Goat Anti-Mouse IgG/HRP 
 


























2.9.6 Isopropyl-ȕ-D-1-thiogalactopyranoside (IPTG) induction 
Isopropyl ȕ-D-1-thiogalactopyranoside (IPTG), a lactose analogue which can activate 
promoters derived from the lac operon, was used to induce pGEX-4T-1-CDKAL1 gene 
expression. Briefly, pGEX-T4-1-CDKAL1 constructs were transformed into the protease 
deficient E.coli BL21 strain. The following day, a representative colony was inoculated 
in 4 mL LB supplemented with 50 µg/mL ampicillin. Two-hundred microlitres of 
overnight culture were grown for a further 15 hours in 4 mL of LB/ampicillin. A 200 µL 
aliquot of the culture was transferred to a 1.5 mL tube and grown in the absence of any 
stimulation (pre-induction sample). Eight microlitres 100 mM IPTG were added to the 
rest of the culture, which was grown for a further 3 hours at 37°C. Three further 200 µL 
aliquots were removed from the culture at 1 hour intervals (post-induction samples). 
Pre- and post induction cultures were centrifuged at 10,000 rpm for 5 min at room 
temperature and the pellet was re-suspended in 200 µL 1X Laemli buffer. Samples were 
denatured at 90°C and stored at -20°C or loaded on an 8% SDS-polyacrylamide minigel 
(Table 2.9.5.1). Samples were run at 120V for 1.5 hours, stained for 1 hour in 
comassium blue and then de-stained for an additional hour in 40% Methanol/10% 
Acetic acid. Gel images were acquired using a PowerShot A640 camera (Canon). 
 
2.10 Statistical analyses  
2.10.1 Power calculations  
The statistical power of the UK case-control dataset was estimated based on published 
data on marker allele frequencies and odds ratios (Scott, Mohlke et al. 2007; Barrett, 
Hansoul et al. 2008). All calculations were carried out using the on-line Genetic Power 
Calculator (available at http://pngu.mgh.harvard.edu/~purcell/gpc/). 
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2.10.2 Genotype imputation  
As CDKAL1 SNP rs6908425 had not been analysed in the CASP study, genotypes were 
imputed using data from neighbouring SNPs. This analysis was carried out using 
PLINK 1.03 (Purcell, Neale et al. 2007) and results were confirmed with MACH (Li, 
Willer et al. 2010). 
 
2.10.3 Analysis of case-control data  
Chi-square tests were implemented on 2 x 3 contingency tables, in order to verify that 
genotype frequencies did not deviate from Hardy Weinberg Equilibrium (HWE). The 
1958 Birth Cohort genotype database (http://www.b58cgene.sgul.ac.uk/) was queried in 
order to confirm that the allele frequencies of associated markers were homogenous 
across the UK. 
Association analyses for the UK dataset were performed by combining the allele 
numbers of cases with those of the WTCCC controls 
(https://www.wtccc.org.uk/index.shtml) in 2 x 2 contingency tables. The genotypes 
generated by the CASP study (data available after registration at 
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study), were analysed with PLINK 
1.03 (Purcell, Neale et al. 2007). The meta-analysis of the UK and CASP data was 
carried out with Review manager 5 (http://ims.cochrane.org/revman/download). 
 
2.10.4 Analysis of linkage disequilibrium conservation  
The conservation of linkage disequilibrium (LD) within disease associated intervals was 
assessed using Haploview 3.32 (http://www.broad.mit.edu/mpg/haploview/). This 
software, which generates a graphic overview of the degree of LD between selected 
SNPs, was used to analyse the data generated by the HapMap consortium (Thorisson, 
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Smith et al. 2005) for the regions of interest.  
 
2.10.5 Multiple testing corrections 
The proportion of true association effects was assessed using two corrections for 
multiple testing. First, corrected p values (pc) were calculated according to the 
Bonferroni formula (pc = p (n-1), where n is the number of analysed SNPs). Next, a 
False Discovery Rate (FDR) was calculated as follows: FDR= NĮ/K, where N= total 
number of SNPs, Į= threshold p value, K= number of SNPs where p d Į) (Benjamini 
1995).  
 
2.11 Bioinformatics  
2.11.1 Evolutionary conservation analysis  
The ClustalW2 software (www.ebi.ac.uk/Tools/clustalw2/index.html) was used to 
analyze the conservation of the putative CDKAL1 domains annotated in the Ensembl 
Genome browser (www.ensembl.org).  
The UCSC (University of California Santa Cruz) genome Browser 
(http://genome.ucsc.edu/index.html) was queried, in order to assess the evolutionary 
conservation of non-coding disease-associated intervals. This analysis was based on the 
multiple alignment of 44 vertebrate genomes.  
 
2.11.2 Analysis of microarray data 
A gene expression profile was generated in quadruplicate for each sh-RNA construct. 
The readings generated by the iScan System (Illumina) were normalized to the 
50thpercentile, using the GenomeStudio software. Normalized data were analyzed with 
the Qlucore Omics Explorer 2.1 software, using default options. The analysis was 
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performed in log2 scale and a t-test was used to generate P values. These were adjusted 
for multiple comparisons by calculating a FDR, using the formula described above 
(Benjamini 1995; Smyth 2004). Gene ontology (GO) analysis, was performed using 
GeneGo MetaCore pathway analysis version 6.4 (GeneGo Inc.), based on the GO terms 
annotated in the Ensembl genome browser. This analysis allows the reconstruction of 
putative cellular pathways, based on the mining of literature databases and the 
expression levels of the analyzed genes. Statistical significance is derived based on the 
overlap between the analyzed dataset and the genes participating to specific cellular 
pathways. Gene expression changes were expressed as log2 ratios.  
Array data from the CASP were obtained from the GAIN database, through dbGaP 
accession number phs000019.v1.p1. Raw data were subjected to quantile normalization 
and expression estimates were computed using the Robust Multichip Average (RMA) 
method (Irizarry, Hobbs et al. 2003). z-scores were calculated for the differentially 
expressed genes, using the formula: , where xi is the expression value of 
the individual being analyzed, x  is the mean expression value of healthy individuals 
and sd the standard deviation. A set of dissimilarities was extracted for each gene and 
hierarchical clustering analysis was implemented using the R software (freely available 
at http://www.R-project.org).  
 
2.11.3 Analysis of real-time PCR data 
The expression of transcripts of interest was normalized to that of the PPIA (encoding 
cyclophilin A) and RPLPO (encoding large PO ribosomal protein) housekeeping genes 
(Table 2.11.3.1). Data analysis was performed using the ''Cycles threshold (Ct) 
method, which does not require the use of a standard curve (Livak and Schmittgen 
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2001; Lopez-Albaitero, Mailliard et al. 2009). The ''Ct value was calculated using the 
formula: ǻǻCt = (CtGOI – CtHK), where CtGOI and CtHK are the averaged Ct values for 
the gene of interest and the housekeeping gene. Data were expressed as mRNA 
expression fold changes, relative to a calibrator sample. Assuming a doubling of 
material during each PCR cycle, this relative quantification (RQ) was estimated 
according to the formula: (RQ) = 2-''Ct.  
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Chapter 3: Genetic analysis of 26 Crohn’s disease (CD) susceptibility loci in 
psoriasis 
 
3.1 Association analysis  
An association study was undertaken, in order to investigate the possibility of a genetic 
overlap between psoriasis and CD. At the onset of this project, GWASs had identified 
32 loci (including IL12B and IL23R) significantly associated with CD (p < 10-5) 
(Parkes, Barrett et al. 2007; The Wellcome Trust Case-Control Consortium 2007; 
Barrett, Hansoul et al. 2008). Power calculations demonstrated that the dataset available 
for this study had adequate power to detect associations at 28 CD loci (Table 3.1.1). On 
this basis, a genotyping panel (Table 3.1.2) was designed, which included one marker 
from each of the relevant CD susceptibility regions. Two markers were typed from the 
1q24 (rs12035082 and rs9286879) and 5q33 (rs11747270 and rs1000113) loci, based on 
reports of associations at two unrelated SNPs (r2 < 0.4) (Parkes, Barrett et al. 2007; The 
Wellcome Trust Case-Control Consortium 2007; Barrett, Hansoul et al. 2008). No 
susceptibility alleles from the CARD15/NOD2 gene were analyzed, as previous studies 
had failed to identify any evidence for an involvement of these variants in psoriasis 
(Nair, Stuart et al. 2001; Borgiani, Vallo et al. 2002; Young, Allen et al. 2003). 
Moreover, CD markers lying on chromosome 6p21 were not analysed, as the linkage 
disequilibrium with PSORS1 alleles would have confounded the interpretation of 
association signals. 
The SNPs listed in Table 3.1.1 were typed in 1,256 psoriatic patients and the resulting 
allele frequencies were compared with those generated by the Wellcome Trust Case 
Control Consortium (WTCCC) for 2,938 controls from the 1958 British Birth Cohort 
and the National Blood Service (The Wellcome Trust Case-Control Consortium 2007). 
The use of control genotypes generated in another centre was validated by typing one 
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randomly selected SNP (rs12035082) in 1,304 individuals from the 1958 British Birth 
Cohort. No discrepancies between these genotypes and the ones from the WTCCC 
study were observed. At the same time, the quality of patient genotype data was 
assessed by investigating deviations from Hardy-Weinberg Equilibrium (HWE). This 
identified a significant departure from HWE for SNP rs11175593 (p = 0.0002). A re-
analysis of the SNP data, based on the direct sequencing of 192 patient samples, 
revealed a number of inaccuracies in the results obtained by TaqMan genotyping. On 
this basis, marker rs11175593 was excluded from all subsequent analyses.  
The comparison of case and control allele frequencies identified significant disease 
associations for four independent markers: rs12035082 (p = 0.009; OR = 1.14; 95% CI: 
1.03-1.25), rs6908425 (p = 0.00015; OR = 1.26; 95% CI: 1.12-1.42), rs2836754 (p = 
0.0003; OR = 1.15; 95% CI: 1.06-1.30) and rs762421 (p = 0.0002; OR = 1.22; 95% CI: 
1.09-1.36). Moreover, associations of marginal significance were identified for SNPs 
rs1000113 (p = 0.045; OR = 1.20; 95% CI: 1.00-1.45) and rs4263839 (p = 0.04; OR = 
0.9; 95% CI: 0.81-0.99). 
In order to address the issue of multiple testing, a Bonferroni correction was applied to 
p values and a False Discovery Rate (FDR) was calculated. Following these analyses, 
four markers (listed in Table 3.1.3) remained associated at a FDR < 0.01 and 3 yielded 
corrected p values < 0.05 (Table 3.1.3). To exclude the possibility that these results may 
reflect the presence of population stratification, the control genotypes of the 1958 
British Birth cohort were examined in more detail. Mining of a public database 
(available at http://www.b58cgene.sgul.ac.uk/) showed that all 3 critical SNPs had 
homogeneous allele frequencies across UK regions, thereby excluding the possibility 
that the associations may be due to the occurrence of hidden population structure. 
Finally, a logistic regression analysis was carried out, using age and sex as covariates. 
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No increase in the significance of p values was observed, indicating that the 

























Table 3.1.1: Power calculations  
       N. cases for 80% power 
Marker OR Chr. Gene* p = 0.05 p = 0.01 
rs12035082 1.14 1q24 - 245 364 
rs9286879 1.19 1q24 - 931 1,385 
rs10801047 1.47 1q31 - 433 644 
rs10210302 1.19 2q37 ATG16L1 731 1,088 
rs9858542 1.17 3p21 MST1 1,043 1,553 
rs17234657 1.16 5p13 - 219 327 
rs6596075 1.55 5q31 SLC22A4 164 245 
rs11747270 1.33 5q33 IRGM 780 1,161 
rs1000113 1.54 5q33 IRGM 344 512 
rs3763313 1.19 6p21 Many 904 1,346 
rs6908425 1.21 6p22 CDKAL1 957 1,424 
rs7746082 1.17 6q21 - 1,021 1,506 
rs6927210 1.13 6q23 - 648 965 
rs2301436 1.21 6q27 CCR6 658 980 
rs1456893 1.18 7p12 - 713 1,062 
rs887822 1.20 7q36 - 233 347 
rs7849191 1.12 9p24 JAK2 1,849 2,752 
rs4263839 1.22 9q32 TNFSF15 528 786 
rs17582416 1.16 10p11 - 997 1,483 
rs6601764 1.16 10p15 - 1,020 1,518 
rs10761659 1.23 10q21 ZNF365 266 396 
rs10883365 1.18 10q24 NKX2-3 770 1,147 
rs7927894 1.16 11q13 C11orf30 1,025 1,526 
rs11175593 1.54 12q12 MUC19 1,291 1,922 
rs2066847 3.99 16q12 NOD2/CARD15 66 98 
rs744166 1.18 17q21 STAT3 797 1,187 
rs2872507 1.12 17q21 ORMDL3 1,610 2,396 
rs2542151 1.35 18p11 PTPN2 368 548 
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rs4807569 1.02 19p13 SBNO2 1,294 1,926 
rs1736135 1.18 21q21 - 822 1,224 
rs2836754 1.15 21q22 FLJ45139 1,141 1,698 
rs762421 1.13 21q22 ICOSLG 618 920 
Calculations were carried out, based on the risk allele frequencies and odds ratios (OR) 
observed in published CD GWASs, assuming the analysis of 2,938 controls. Markers 
that were excluded from further analyses, due to lack of power are highlighted in bold. 
Markers from the IL23R and IL12B loci were not included in the power calculations or 
in further analyses, as associations with psoriasis had already been established. * Gene 




Table 3.1.2: Association analysis results 
   
Allele Counts 
(Minor Allele Frequency) 
  
Marker Chr. Gene* Cases Controls OR p value 




















rs9858542 3p21 MST1 0.29 (692/2360) 
0.28 
(1652/5862) 1.06 0.30 















































































































*Gene found in the susceptibility interval tagged by the examined SNP. OR: odds ratio 





Table 3.1.3: Association results for SNPs generating a FDR < 0.01 
   Minor allele 
frequency 
   
Marker Chr. Gene* Cases Controls p value pc 
value 
OR 
rs12035082 1q24 - 0.42 0.39 0.009 0.24 1.14 
rs6908425 6p22 CDKAL1 0.19 0.23 0.00015 0.004 0.79 
rs2836754 21q22 FLJ45139 0.39 0.35 0.0003 0.008 1.17 
rs762421 21q22 ICOSLG 0.34 0.39 0.0002 0.005 0.84 
* Gene found in the susceptibility interval tagged by the examined SNP. OR: odds ratio 
for the minor allele; pc value: p value following Bonferroni correction. The bold font 













3.2 Characterization of three psoriasis associated loci  
The genotype data generated by the HapMap Consortium (Frazer, Ballinger et al. 2007) 
were analyzed, with a view to defining the genomic regions tagged by the three disease 
associated SNPs. The results of this analysis are shown in Figures 3.2.1, 3.2.2 and 
3.2.3.  
rs6908425 is a non-coding C/T SNP, which lies on chromosome 6p22.3, within intron 5 
of the CDKAL1 gene. The SNP is located in close proximity of a 48 kb LD block, 
which includes one SNP (rs10946398) previously associated with type 2 diabetes 
(T2D) (Saxena, Voight et al. 2007; Scott, Mohlke et al. 2007; Zeggini, Weedon et al. 
2007). Although SNPs rs6908425 and rs10946398 lie in the same CDKAL1 intron, they 
are not in LD with each other (r2 = 0.04) (Fig. 3.2.1). 
rs2836754 is a non-coding C/T SNP, which lies in intron 2 of the FLJ45139 anonymous 
transcript, on chromosome 21q22.2. The SNP maps to a 3 kb LD block, which is 
delimited by markers rs8129427 (r2 with rs2836754: 0.02) and rs2410067 (r2 with 
rs2836754: 0.03) (Fig. 3.2.2). This block also contains several genomic segments that 
are highly conserved among mammals. 
rs762421 is a non-coding G/A SNP, which lies on chromosome 21q22.3, in a gene 
desert, upstream of the ICOSLG transcript. The SNP maps to a 19 kb LD block, which 
is delimited by markers rs9976849 (r2 with rs762421: 0.21) and rs2838528 (r2 with 







 Figure 3.2.1: Overview of linkage disequilibrium conservation around SNP 
rs6908425 
The position of marker rs6908425 is indicated by a red circle. The position of the T2D 
susceptibility marker (rs10946398) is indicated by a green circle. The blue square 
highlights the lack of correlation between rs6908425 and rs10946398 (r2: 0.04). The 
diagram below the LD plot indicates the position of the investigated region with respect 
to chromosome 6 coordinates and CDKAL1 intron 5. 
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Figure 3.2.2: Overview of linkage disequilibrium conservation around SNP 
rs2836754 
SNP rs2836754, which is indicated by a red circle, lies in a 3 kb LD block, delimited by 
markers rs8129427 and rs2410067 (green circles). Green squares highlight the r2 
between rs2836754 and rs8129427 (r2: 0.02) and that between rs2836754 and 
rs2410067 (r2: 0.03). The arrow below the LD plot indicates the position of the 
investigated region with respect to chromosome 21 coordinates and the genomic 














Figure 3.2.3: Overview of linkage disequilibrium conservation around SNP 
rs762421 
SNP rs762421, which is indicated by a red circle, lies in a 19 kb LD block, delimited by 
markers rs9976849 and rs2838528 (green circles). Dark green squares highlight the r2 
between rs762421 and rs9976849 (r2: 0.21) and that between rs762421 and rs2838528. 
The arrow below the LD plot indicates the position of the investigated region with 




















3.3 Replication analysis of disease associated SNPs  
To validate the observed disease associations, the genome-wide data generated by the 
Collaborative Association Study of Psoriasis (CASP) (Nair, Duffin et al. 2009) was 
queried. The study was based on the analysis of 1,348 cases and 1,368 controls and 
good quality SNP genotypes (call rate > 90%, p value for HWE > 0.05) were available 
for psoriasis associated markers rs2836754 (chr. 21q22) and rs762421 (chr. 21q22). As 
SNP rs6908425 (chr. 6p22) was not present in the Perlegen array used to generate the 
CASP data, the genotypes for this marker were imputed, based on those of neighbouring 
SNPs. 
The results of the CASP dataset association analysis are summarized in Table 3.3.1.  
A p value of 0.06 was observed for SNP rs2836754, at the FLJ45139 locus. The 
analysis of neighbouring SNPs identified significant associations (p < 0.01) for at least 
three markers (rs2142107, rs13047416 and rs2836773), but an examination of LD 
conservation patterns failed to reveal any correlation between rs2836754 and the 
relevant SNPs. In fact the r2 values between rs2836754 and rs2142107 (yielding a p of 
0.0086), rs13047416 (p = 0.0086) and rs2836773 (p = 0.002) only range between 0.24 
and 0.46 (Fig. 3.3.1). 
Neither rs762421 nor any of its neighbouring SNPs in the ICOSLG gene region showed 
any significant association with psoriasis.  
Finally, the comparison of case and control imputed allele frequencies for CDKAL1 
SNP rs6908425 generated a p value equal to 0.00012. 
In the subsequent phase of the study, combined p values were calculated for the three 
critical markers, through a meta-analysis of the UK and CASP datasets. The results are 
reported in Table 3.3.1.  
The significance of the association for SNP rs2836754 (FLJ45139 locus) decreased in 
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the overall dataset, compared to the UK sample.  
The marker lying in the ICOSLG gene region (rs762421) could not be analysed across 
the UK and CASP datasets, because of evidence of heterogeneity between the two 
samples (p = 0.01; I2 = 83.9%). Thus, only CDKAL1 SNP rs6908425 generated a 
convincing association in both the discovery and the replication datasets. No evidence 
of heterogeneity was detected between the two samples (p= 0.85; I2 = 0%) and a meta-
analysis of the two studies yielded a combined p value of 4 × 10í6 (OR: 1.26; 95% CI: 











































































*based on imputed genotypes; ** N/A: Non applicable, as the meta-analysis uncovered 
evidence for heterogeneity between the two samples. OR: odds ratio for the minor 

















Figure 3.3.1: Position of linkage disequilibrium blocks around SNP rs2836754 
SNP rs2836754, indicated by a red circle, lies in a 3 kb LD block. Markers rs2142107, 
rs13047416 and rs2836773 (indicated by green arrows), which have shown association 
in the CASP study, map to different LD blocks. Blue circles indicate the correlation 
between rs2836754 and rs2142107 (r2: 0.41); rs2836754 and rs13047416 (r2: 0.46); 
rs2836754 and rs2836773 (r2: 0.24). The arrow below the LD plot indicates the position 
of the investigated region with respect to chromosome 21 coordinates and the genomic 
organization of FLJ45139. 
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 3.4 Analysis of allelic heterogeneity at the CDKAL1 locus 
The analysis of the data generated by the CASP project for the CDKAL1 locus identified 
significant disease associations (p < 0.01) for several SNPs. Of note, many of these 
markers were not correlated with rs6908425 (r2  0.05), suggesting the presence of 
allelic heterogeneity. To further investigate this possibility, four representative SNPs, 
unrelated to each other and to rs6908425, were selected for follow-up in the UK dataset 
(Fig. 3.4.1 and Table 3.4.1). These SNPs were genotyped in 962 UK psoriatic cases and 
the resulting allele frequencies were compared to those of the 2,938 unrelated controls 
analyzed by the WTCCC. Following the quality control of genotype data, a significant 
departure from HWE (p = 0.0007) was identified for one of the examined SNPs 
(rs4454125), which was not analyzed any further. Despite evidence for power (Table 
3.4.1), no significant association with psoriasis was identified for any of the remaining 




































Figure 3.4.1: Overview of linkage disequilibrium conservation across the CDKAL1 
gene 
The position of marker rs6908425 is indicated by a red circle. The positions of SNPs 
showing association in the CASP study are indicated by blue arrows. The LD plot 
shows that psoriasis associated SNPs rs714831, rs7752602, rs4454125 and rs714830 are 
independent from rs6908425, as shown by the r2 values highlighted by blue circles. The 
arrow below the LD plot indicates the position of the investigated region with respect to 


































Table 3.4.1: Power calculations for SNPs 
rs714831, rs714830, rs4454125 and rs775202 
 
 N. cases for 80% power 










rs7752602 575 855 
Calculations were carried out, based on the minor 
allele frequencies and odds ratios observed in the 





Table 3.4.2: Analysis of allelic heterogeneity at the CDKAL1 locus 
  Allele Counts 


















































3.5 Analysis of type 2 diabetes susceptibility SNPs in the psoriasis dataset 
GWASs have identified associations with T2D for several correlated markers lying 
within CDKAL1 intron 5 (rs10946398, rs9465871, rs7767391) (Scott, Mohlke et al. 
2007; Zeggini, Weedon et al. 2007). To explore the relationships between the T2D and 
psoriasis association signals, the data generated by the HapMap consortium for the 
CDKAL1 region was queried. This analysis revealed a complete lack of correlation 
between psoriasis and T2D associated markers, as the r2 values between rs6908425 and 
rs10946398, rs9465871, rs9460546 were all  0.04 (Fig. 3.5.1). This observation 
indicates that the two association signals are unrelated, but does not exclude the 
possibility that T2D SNPs may confer susceptibility to psoriasis, independently from 
rs6908425. To better investigate this hypothesis, a case-control study was carried out for 
the marker showing the strongest association with T2D (rs10946398). This SNP was 
genotyped in 962 UK psoriatic cases and the resulting allele frequencies were compared 
to those of the 2,938 unrelated controls analyzed by the WTCCC. Although the dataset 
had adequate statistical power to detect an association with rs10946398 (Table 3.5.1), 
none was observed (p = 0.60).  
Finally, the relationship between the CD and the T2D associations was examined. For 
this purpose, the data generated by the WTCCC for CD (The Wellcome Trust Case-
Control Consortium 2007) was queried, to assess the presence of a disease association 
with the T2D marker. Despite the adequate power of the dataset, which included 1,747 
patients and 2,938 controls (Table 3.5.1), no association was detected between 
rs10946398 and CD (p = 0.84). 
Taken together, these data support the presence of an allelic series at the CDKAL1 locus, 















Figure 3.5.1: Overview of linkage disequilibrium conservation across the CDKAL1 
locus 
The position of marker rs6908425 is indicated by a red circle. The positions of SNPs 
showing association with T2D are indicated by green arrows. The LD plot shows that 
the T2D susceptibility SNPs are independent from rs6908425, as shown by the r2 values 
highlighted by dark green circles. The arrow below the LD plot indicates the position of 
the investigated region with respect to chromosome 6 coordinates and the genomic 


































Table 3.5.1: Power calculations for SNP rs10946398 
 N. cases for 80% power 
Marker p = 0.05 p = 0.01 OR 
rs10946398 633 943 1.2 
Calculations were carried out, based on the minor allele 
frequencies and odds ratios observed in the WTCCC 










































The existence of shared genetic determinants for clinically distinct inflammatory 
disorders is clearly documented by the results emerging from several GWASs (Seldin 
and Amos 2009). In this context, the aim of this study was to specifically investigate the 
genetic overlap between psoriasis and CD, based on the observation that at least two 
genes (IL23R and IL12B) harbor alleles conferring susceptibility to both conditions 
(Duerr, Taylor et al. 2006; Capon, Di Meglio et al. 2007; Cargill, Schrodi et al. 2007; 
Barrett, Hansoul et al. 2008). To achieve this purpose, an association analysis was 
undertaken, by genotyping 28 markers that had been associated with CD in GWASs 
carried out prior to the onset of this study (Parkes, Barrett et al. 2007; Barrett, Hansoul 
et al. 2008). This identified three CD markers (rs6908425, rs2836754 and rs762421) 
that were associated with psoriasis at an FDR < 0.01. Given the evidence for adequate 
statistical power in the study dataset, the lack of association at the other loci is likely to 
reflect genuine differences in the genetic architecture of psoriasis and CD.  
The analysis of an independently ascertained case-control dataset (the CASP study) 
validated the association for CDKAL1 marker rs6908425. The lack of association at the 
two remaining loci may reflect the lower statistical power of the CASP dataset 
(including 1,348 cases and 1,368 controls) compared with the UK resource (1,256 cases 
and 2,938 WTCCC controls).  
Of interest, a number of CDKAL1 markers unrelated to rs6908425 were found to be 
significantly associated with psoriasis in the CASP study. However, the analysis of 
these SNPs in the UK dataset failed to reveal any evidence of association, with one 
marker also showing a significant departure from HWE. These observations suggest that 
these particular CASP findings are likely to represent false positive results, possibly 
reflecting the difficulty of genotyping some CDKAL1 markers. 
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Marker rs6908425 maps in intron 5 of CDKAL1, which also harbours a cluster of SNPs 
that have been repeatedly associated with T2D (Saxena, Voight et al. 2007; Scott, 
Mohlke et al. 2007; Steinthorsdottir, Thorleifsson et al. 2007; Zeggini, Weedon et al. 
2007). T2D is a common condition and its frequency in the UK is approximately 5-10% 
(Penn, White et al. 2009). There is also clinical evidence that psoriatic patients are at 
higher risk to develop T2D than the general population (Gottlieb and Dann 2009). Thus, 
a significant minority of the patients from the UK and CASP datasets are likely to be 
affected by T2D, as well as psoriasis. Although this is undoubtedly a confounding 
factor, the possibility that the association seen in the UK and CASP cohorts could be 
solely determined by the subset of patients with T2D is unlikely, given the poor 
statistical power afforded by this subgroup.  
To further explore the relationships between the T2D and psoriasis association signals, a 
CDKAL1 SNP associated to T2D (rs10946398) was analysed in the UK psoriasis 
dataset. Despite the adequate statistical power of this sample, no evidence for 
association was observed. Likewise, an analysis of the data generated by the WTCCC 
failed to reveal any evidence of association between rs10946398 and CD.  
Taken together, the results presented in this chapter identify CDKAL1 as a novel 
psoriasis susceptibility gene and indicate the presence of an allelic series, whereby 
distinct intron 5 SNPs confer susceptibility to inflammatory (CD, psoriasis) and 












Chapter 4: Analysis of CDKAL1 gene expression 
 
4.1 The CDKAL1 locus  
CDKAL1 lies on chromosome 6p22.3, where it spans a 697,948 base pair (bp) region, 
extending from position 20,534,688 to 21,232,635, in the GRCh37 human genome 
assembly. Five CDKAL1 isoforms are annotated in the Ensembl genome browser 
(release 56): CDKAL1-201, CDKAL1-202, CDKAL1-203, CDKAL1-001 and CDKAL1-
002. These transcripts differ in the length of their untranslated regions (UTRs) and in 
the number of coding exons (Fig 4.1.1). CDKAL1-201 measures 2,408 bp and 
represents the full length transcript. It consists of 16 exons and encodes a 579 amino 
acid (Aa) protein that has a predicted molecular weight of 65 kDa. CDKAL1-202 spans 
1,784 bp and lacks exons 4 and 13, as well as the final portion of the gene 3’ UTR. It 
encodes a 488 Aa protein with a predicted molecular weight of 55 kDa. CDKAL1-203 
includes all 16 exons, but only measures 1,960 bp, as its 3’ UTR is shorter than that of 
the full length mRNA. CDKAL1-001 spans 3,115 bp; it lacks non-coding exons 1 and 2, 
but includes a longer 3’ UTR region, compared to the full length transcript. CDKAL1-
002 is 840 bp in length and its sequence includes two non-coding exons lacking an ATG 







 Figure 4.1.1: Graphic representation of CDKAL1 isoforms 
Black and blue bars represent coding and non-coding transcripts, respectively. Red 
squares indicate the position of the various exons. Ex: exon. 














4.2 Experimental analysis of CDKAL1 transcript isoforms 
CDKAL1-202 is the only isoform that is predicted to encode a smaller protein product 
than the one generated by the full length transcript. For this reason, an RT-PCR analysis 
was carried out, to specifically investigate CDKAL1-202 tissue distribution. RT-PCR 
primers annealing to exon one and sixteen were designed, in order to amplify the full 
length cDNA as well as transcripts lacking exons four and thirteen. The primers were 
used to amplify a panel of 11 cDNAs derived from a variety of tissues, including several 
that are affected by T2D (skeletal muscle, pancreas), CD (CD4+ and CD8+ T 
lymphocytes, colon) and psoriasis (CD4+ and CD8+ T lymphocytes, skin keratinocytes). 
Electrophoresis analysis of the RT-PCR products showed the amplification of a single 
band, in all examined tissues (Fig.4.2.1). The molecular weight of the band was 
consistent with that of the full-length cDNA and sequence analysis confirmed that the 
RT-PCR product was indeed CDKAL1-201. Thus the CDKAL1-202 isoform was not 













 Figure 4.2.1: Electrophoresis analysis of CDKAL1 RT-PCR products 
A single amplification product consistent with the size of the full-length cDNA (1,960 
bp, based on the position of RT-PCR primers) was visualized on the gel. CD4+: CD4+ T 
















4.3 Analysis of CDKAL1 tissue distribution  
The function of the CDKAL1 protein is currently unknown and only limited 
information is available on the gene expression pattern, as previous studies mainly 
focused on tissues that are relevant to the pathogenesis of T2D (Scott, Mohlke et al. 
2007; Zeggini, Weedon et al. 2007). To address this issue, a comprehensive 
characterization of CDKAL1 transcript levels was performed by real-time PCR, using a 
panel of cDNAs derived from 20 tissues and cell types. This analysis revealed a 
widespread gene expression pattern, with CDKAL1 transcripts detectable in all 
examined tissues. In agreement with published data (Scott, Mohlke et al. 2007), very 
strong CDKAL1 expression was observed in skeletal muscle, more than two-fold higher 
than in the brain. Weaker expression levels were also detected in the pancreas, liver and 
kidney (Fig.4.3.1). Surprisingly, in CD target tissues such as the small intestine and 
colon, the expression of CDKAL1 was low. A similar expression pattern was observed in 
skin keratinocytes, a cell type proven to play a role in psoriasis pathogenesis. 
Conversely, CDKAL1 was strongly expressed in immune cells, such as CD4+ T 
lymphocytes, CD8+ T lymphocytes, CD19+ B lymphocytes and monocytes (Fig.4.3.1). 
CDKAL1 expression was further investigated in lymphocytes and keratinocytes, as these 
are the main cell types contributing to the pathogenesis of psoriasis.  
Cultured primary keratinocytes, obtained from skin biopsies of one healthy and one 
psoriatic donor, were treated with a panel of pro-inflammatory molecules (IFN-Į, IFN-
Ȗ, TNF-Į, IL-17, IL-22 and IL-23) and the relevant cDNAs were analyzed by real-time 
PCR. As shown in Fig.4.3.2A, no changes in CDKAL1 expression were observed in 
normal primary keratinocytes, following treatment with any of the examined cytokines. 
However, a marked CDKAL1 down-regulation was detected in psoriatic keratinocytes 
treated with IL-17, IL-23 and IFN-Į (Fig. 4.3.2B). 
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To explore the role played by CDKAL1 in lymphocytes, the gene expression was 
investigated in mitogen-activated T and B cells. Real-time PCR experiments were 
carried out on commercially available cDNAs, obtained from pools of resting and 
activated CD4+, CD8+ and CD19+ lymphocytes. These cells had been purified from 
blood samples of healthy donors and had been activated with concavalin A (CD4+ T 
lymphocytes), phytohaemoagglutinin (CD8+ T lymphocytes) and pokeweed mitogen 
(CD19+ B lymphocytes). Following the analysis of real-time PCR results, a significant 
down-regulation of CDKAL1 expression was detected in activated and proliferating 
lymphocytes, compared to non-activated, resting cells (Fig. 4.3.3A). In order to exclude 
the possibility that mitogen activation had resulted in the differential expression of the 
housekeeping gene (PPIA) used in the real-time PCR experiments, an additional 
analysis was performed using an alternative endogenous control (RPLPO). This 
confirmed the previous set of results, indicating that CDKAL1 is genuinely down-













 Figure 4.3.1: Real-time PCR analysis of CDKAL1 gene expression 
Transcript levels were quantified using the PPIA housekeeping gene as an endogenous 
control. The CDKAL1/PPIA ratio in brain was set as a baseline value to which all 
transcript levels were compared. CD4+: CD4+ T lymphocytes; CD8+: CD8+ T 
lymphocytes; CD19+: CD19+ B lymphocytes. Error bars refer to technical duplicates in 




















Figure 4.3.2: Real-time PCR analysis of CDKAL1 expression in primary 
keratinocytes 
Following cytokine stimulation, (100ng/mL for 24 hours for IL-17, IL-22, IL-23, IFN-Ȗ 
and TNF-D; 5 hours for IFN-Į), no differences in CDKAL1 expression were detected in 
normal keratinocytes (A). Conversely, a marked CDKAL1 down-regulation was 
detected in psoriatic keratinocytes treated with IL-17, IL-23 and IFN-Į (B). The PPIA 
housekeeping gene was used as an endogenous control and the CDKAL1/PPIA ratio for 
PBS treated samples was set as a baseline value to which all transcript levels were 
normalized. Error bars refer to technical duplicates in real-time PCR experiments. The 












 Figure 4.3.3: Real-time PCR analysis of CDKAL1 expression in resting and 
activated lymphocytes 
A significant CDKAL1 down-regulation was detected in activated T and B cells. The 
CDKAL1/PPIA ratio for CD4+ T lymphocytes was set as a baseline value, to which all 
transcript levels were normalized (A). The CDKAL1/RPLPO ratio for CD4+ T 
lymphocytes was set as a baseline value (B). Error bars refer to technical duplicates in 
real-time PCR experiments. CD4+: resting CD4+ T lymphocytes; Ac CD4+: activated 
CD4+ T lymphocytes; CD8+: resting CD8+ T lymphocytes; Ac CD8+: activated CD8+ T 
lymphocytes; CD19+: resting CD19+ B lymphocytes. Ac CD19+: activated CD19+ B 
lymphocytes. Significance values were calculated using the t-test. *p< 0.05; **p< 0.01. 
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4.4 Discussion  
The aim of the experiments described in this chapter was to explore CDKAL1 
expression, with a view to obtaining some preliminary insights into the mechanisms 
through which the gene may contribute to disease susceptibility. The first phase of the 
study consisted of a bioinformatic analysis of CDKAL1 transcripts, which revealed the 
presence of five distinct mRNA isoforms. Importantly, one of these transcripts 
(CDKAL1-202) lacked two coding exons and was therefore expected to generate a 
smaller protein product than the one encoded by the full-length mRNA. For this reason, 
the tissue distribution of isoform CDKAL1-202 was investigated at the experimental 
level, by analyzing a panel of cDNAs derived from 11 tissues and cell types. These 
experiments failed to detect the presence of the CDKAL1-202 transcript in any of the 
examined tissues. At the same time, the annotation data available in the Ensembl 
genome browser indicate that CDKAL1-202 is expressed in at least one of the analysed 
tissues (placenta, which is the source of the EST sequence supporting the existence of 
CDKAL1-202). Thus it is still possible that CDKAL1-202 may be present in the 
examined samples, but at levels that are too low for detection by conventional RT-PCR.  
All CDKAL1 isoforms differ from the full length transcript in the length of their 5’ 
(CDKAL1-001) and 3’UTRs (CDKAL1-001, CDKAL1-202, CDKAL1-203). Since 5’ 
UTRs contain ribosome binding sites (Pickering and Willis 2005) and 3’UTRs are 
involved in the stabilization of mRNAs (Muhlrad and Parker 1999), it is possible that 
variations in the length of these regions may have an effect on gene expression levels, 
resulting in the differential regulation of the various isoforms. 
Limited information is available on CDKAL1 tissue distribution, as published studies 
mainly focused on tissues relevant to the pathogenesis of T2D (Scott, Mohlke et al. 
2007; Zeggini, Weedon et al. 2007). In order to generate a broader overview of 
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CDKAL1 tissue distribution, a comprehensive characterization of transcript levels was 
performed, using a panel of cDNAs derived from 20 cell types. In agreement with 
published data (Scott, Mohlke et al. 2007), this experiment highlighted a very strong 
CDKAL1 expression in skeletal muscle, a tissue that plays an important role in the 
pathogenesis of T2D. Of note, RT-PCR analyses also revealed abundant CDKAL1 
expression in several immune cell types, suggesting that CDKAL1 might have a role in 
the inflammatory responses that underlie psoriasis and CD susceptibility. This 
observation was further supported by the analysis of cDNAs obtained from resting and 
activated T and B cells, which showed a marked change in CDKAL1 expression, upon 
lymphocyte activation. 
RT-PCR experiments also revealed modest CDKAL1 levels in primary keratinocytes. 
Although these cells had only been passaged for a limited number of times, it is still 
possible that the culture conditions may have influenced the expression of CDKAL1. 
Thus, it is difficult to compare the transcript levels observed in these cells, with those 
detected in fresh tissues. Of note, CDKAL1 down-regulation was observed in primary 
psoriatic keratinocytes after treatment with IL-17, IL-23 and IFN-Į, three pro-
inflammatory cytokines that have emerged as key players in the immunopathogenesis of 
psoriasis (Nestle and Gilliet 2005; Di Cesare, Di Meglio et al. 2009). These expression 
data were generated in keratinocytes obtained from a single patient and should therefore 
be interpreted with caution. However, it is noteworthy that the results of these 
experiments further support the idea that CDKAL1 may be involved in inflammatory 
processes.  
Taken together, the findings presented in this chapter indicate that CDKAL1 is a widely 
expressed gene which might be differentially regulated by a variety of cis- (UTRs of 
different length) and trans- (cytokines) acting factors. The expression data also suggest 
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Chapter 5: Functional analysis of the CDKAL1 protein 
 
5.1 Bioinformatics 
The homology data annotated in the Ensembl genome browser indicate that CDKAL1 
may be a member of the methylthiotransferase (MTTase) gene family (Fig 5.1.1), which 
encodes several proteins promoting the methylthiolation of tRNAs. This process, which 
is essential for accurate protein translation by the ribosome, involves the modification of 
the adenosine adjacent to the 3’end of the anticodon (Arragain, Handelman et al. 2010). 
MTTases typically include three functional domains: an N-terminal MTTase motif, a 
central radical-S-adenosylmethionine (SAM) and a C-terminal TRM2 and MiaB 
(TRAM) domain (Anton, Saleh et al. 2008), all of which appear to be present within the 
CDKAL1 protein sequence (Fig 5.1.1). Comparative analyses show that the portions of 
CDKAL1 corresponding to these three putative domains are very strongly conserved 
(Fig 5.1.2). The functional importance of these regions is also consistent with the lack 
of non-conservative SNP within the corresponding CDKAL1 exons (Fig. 5.1.3).  
The Ensembl annotation for the CDKAL1 protein also indicates the presence of a 
putative transmembrane motif (Fig. 5.1.1). However, the poor evolutionary conservation 
of this region (Fig. 5.1.2) and the presence of deleterious sequence variants (Fig. 5.1.3) 






































Figure 5.1.1: Graphic representation of CDKAL1 domains 
Coloured bars indicate the position of the domains annotated in the databases listed on 















Figure 5.1.2: Comparative analysis of the CDKAL1 protein sequence 
The alignment of CDKAL1 protein sequences shows a high conservation of the 
MTTase, Radical_SAM and TRAM domains. Amino acids with similar chemical 
properties are highlighted with the same colour. “*”: totally conserved residues; “:”: 



















 Figure 5.1.3: CDKAL1 amino acid sequence variation 
The distribution of CDKAL1 sequence variants was assessed, based on the data 
reported in the Ensembl genome browser. This analysis showed that the predicted 











5.2 Validation of a Į-CDKAL1 antibody 
At the time these functional studies were first undertaken, only one Į-CDKAL1 
antibody was commercially available. When used in western blot experiments, the 
antibody detected a weak 65 kDa signal, consistent with the predicted size of the 
CDKAL1 protein, together with a stronger 55 kDa band, which was found in all 
examined cell types (Fig. 5.2.1). In order to elucidate which of the two bands, if any, 
corresponded to the CDKAL1 protein, a number of experiments were undertaken, with 
a view to assessing the antibody’s specificity.  
The ability of the antibody to recognize a recombinant CDKAL1 protein was first 
investigated. The CDKAL1 full-length cDNA sequence was cloned into the pGEX-4T-1 
vector (Fig. 5.2.2), which encodes a glutathione-S-transferase (GST) protein. A fusion 
protein was subsequently generated by transforming the GST-CDKAL1 construct in 
bacterial cells and inducing its expression by IPTG treatment. As shown in Figure 5.2.3, 
a time-dependent increase in the intensity of a 91 kDa band (consistent with the 
combined molecular weight of the GST moiety and a 65 kDa protein) was observed in 
the bacterial cultures, following IPTG-treatment. The pre- and post-induction samples 
were next analysed by western blot, using Į-CDKAL1 and Į-GST antibodies. As shown 
in Figure 5.2.4, both antibodies detected a clear signal at 91 kDa, demonstrating that the 
protein induced by IPTG treatment and recognized by Į-CDKAL1 is indeed GST-
CDKAL1.  
The specificity of the antibody was next validated in cells where CDKAL1 expression 
had been transiently knocked-down by RNA interference (RNAi). A specific down-
regulation of the 65 kDa band was observed in immortalized keratinocytes (HaCaT cell 
line) (Fig. 5.2.5), whereas the intensity of the 55 kDa signal remained unchanged. These 
data further support the notion that the 65 kDa band is generated by binding of the 
 140

























 Figure 5.2.1: CDKAL1 western blot analysis 
The expression of a 55 kDa and a 65 kDa band (highlighted by black arrows) was 



















 Figure 5.2.2: GST-CDKAL1 sequence analysis 
Plasmid sequence analysis confirmed that the CDKAL1 cDNA had been cloned in frame 
with the GST moiety. Green and blue fonts respectively indicate the GST and CDKAL1 
amino acidic sequences. The red box shows the position of CDKAL1 start codon. The 


















 Figure 5.2.3: Induction of GST-CDKAL1 expression 
A time-dependent increase of the GST-CDKAL1 band intensity was detected after 
isopropyl ȕ-D-1-thiogalactopyranoside (IPTG) treatment. L: molecular weight ladder; 








 Figure 5.2.4: Western blot analysis of IPTG induction 
The same 91 kDa band (corresponding to GST-CDKAL1) was detected using both Į-
CDKAL1 and Į-GST antibodies. L: molecular weight ladder; pre-ind.: pre-induction 








 Figure 5.2.5: Į-CDKAL1 antibody specificity characterization 
RNAi treatment caused a marked down-regulation of CDKAL1 mRNA (panels A and 
B). At the protein level (panel C), a specific down-regulation of the 65 kDa band 
(highlighted by a black arrow) was observed, whereas no change in intensity was 











5.3 CDKAL1 subcellular localization  
Following its validation, the Į-CDKAL1 antibody was used in western blot and 
immunofluorescence experiments, with the aim of establishing CDKAL1 subcellular 
localization. Western blots of extracts obtained from HaCaT and Jurkat cell lines 
demonstrated that CDKAL1 expression can only be detected in the cytoplasmic fraction 
of these cells (Fig. 5.3.1). The analysis of known nuclear (lamin-Į) and cytoplasmic (ȕ-
actin) proteins confirmed the purity of the two fractions. 
The localization of CDKAL1 was also verified by IF staining of HaCaT cells. This 
showed a strong cytoplasmic staining for CDKAL1, with no signal detected in the 

















 Figure 5.3.1: CDKAL1 is expressed in the cytoplasmic cell fraction 
CDKAL1 expression is only detectable in the cytoplasmic fraction of HaCaT and Jurkat 
cells. Detection of known nuclear (lamin-Į) and cytoplasmic (ȕ-actin) proteins 
















Figure 5.3.2: CDKAL1 localizes to the cell cytoplasm 
IF staining of HaCaT cells confirmed the cytoplasmic localization of CDKAL1 (A), 
while cells stained with an isotype control antibody showed no signal (B). Nuclei were 






5.4 Generation of stable CDKAL1 knock-down cell lines 
Stable CDKAL1 knock-down cell lines were generated at the outset of the study as a 
tool to investigate the function of the CDKAL1 protein. 
Two commercial vectors, each encoding a distinct short hairpin RNA (sh-A11 and sh-
H6, see Table 5.4.1), were used to knock-down CDKAL1 expression, in both HaCaT 
and Jurkat cell lines. A non-silencing plasmid, carrying a sh-RNA sequence with no 
homology to known mammalian genes (sh-non-sil.), was used as a negative control for 
both cell types. In all vectors, the sh-RNAs were encoded by a bicistronic transcript that 
also contained the turbo Green Fluorescent Protein (tGFP) gene.  
Stable knock-down cell lines were generated by initially co-expressing the virus 
packaging vectors (pGIPZ-shRNA, VSV-G expressor and p8.91 gag-pol plasmids) in a 
HEK293T cell line. The efficiency of this procedure was demonstrated by the high 
number of tGFP-expressing cells (Fig. 5.4.1). The cell medium containing the viral 
particles was next used to transduce both HaCaT and Jurkat cells. The HaCaT 
transduction efficiency of cells was confirmed by the high frequency of tGFP-
expressing cells (Fig. 5.4.2). In Jurkat cells, the transduction efficiency was assessed by 
flow cytometry, as optical estimation of fluorescence is difficult to achieve in cell lines 
growing as a suspension. As shown in Figure 5.4.3, a transduction efficiency exceeding 
75% was estimated in these cells, based on tGFP fluorescence. 
The degree of CDKAL1 knock-down was next assessed by real-time PCR. No 
significant differences in the levels of CDKAL1 expression were observed in the knock-
down cells, compared to the controls transduced with the non-silencing construct (Fig. 
5.4.4). These results suggested variability in the knock-down efficiency of both HaCaT 
and Jurkat cell lines, possibly due to the number of sh-RNA copies integrated in their 
genomes. To circumvent this problem, a number of clonal lines were generated from 
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single cells, selected for high levels of tGFP-expression (Fig. 5.4.5). Twelve HaCaT and 
six Jurkat clones were thus successfully expanded (Table 5.4.2 and 5.4.3). Real-time 
PCR analysis confirmed a significant down-regulation of CDKAL1 mRNA in seven 
HaCaT (three sh-A11 and four sh-H6) and two Jurkat (both sh-H6) clones. The 
efficiency of knock-down was further confirmed in HaCaT and Jurkat cells that had 
been cultured for four weeks, thus demonstrating the stability of the clones (Tables 5.4.2 




















Table 5.4.1: Short hairpin sequences used to knock-down CDKAL1 expression 
sh-RNA Open biosystems 
identifier 























*The mir-30 backbone sequence is represented by black font; the sense and antisense 
















 Figure 5.4.1: HEK293T cell line transfection efficiency 
All three sh-RNA constructs were efficiently transfected into HEK293T cells, as 










 Figure 5.4.2: HaCaT cell line transduction efficiency 
Lentiviral particles bearing the three sh-RNA constructs were efficiently transduced into 













 Figure 5.4.3: Jurkat cell line transduction efficiency 
A transduction efficiency exceeding 75% was estimated for all transduced cells, based 
on tGFP staining. Cells were first gated based on their size and granularity, as measured 
by the Forward (FSC-A), and Side Scatter (SSC-A) (left-hand plots). Next, tGFP 
fluorescence was detected in the FITC-A channel and cells were gated, based on the 
fluorescence values observed in unstained and untransfected cells. The tGFP expressing 
cells thus detected are highlighted in blue. The percentage figures in the plots indicate 






 Figure 5.4.4: Real-time PCR analysis of CDKAL1 gene expression in stably 
transduced HaCaT and Jurkat cell lines 
No differences in CDKAL1 expression were detected in cells transduced with sh-RNA 
silencing constructs, in either HaCaT (A) or and Jurkat cells (B). Transcript levels were 
quantified using the PPIA housekeeping gene as an endogenous control. Error bars refer 














 Figure 5.4.5: Clonal expansion of transduced HaCaT cells 
Clones were obtained starting from a single, tGFP expressing cell (left panel), which 



















Table 5.4.2: sh-CDKAL1 HaCaT clones 














































*Transcript abundance measured by real-time PCR and expressed as percentage of 
CDKAL1 levels in silenced clones compared to non-silenced ones. The clones selected 






Table 5.4.3: sh-CDKAL1 Jurkat clones 






























*Transcript abundance measured by real-time PCR and expressed as percentage of 
CDKAL1 levels in silenced clones compared to the non-silenced ones. The clones 














 Figure 5.4.6: Real-time PCR analysis of CDKAL1 gene expression in clones derived 
from stably transduced HaCaT and Jurkat cell lines 
A significant down-regulation of CDKAL1 expression was detected in the majority of 
analysed clones, in both HaCaT (A) and Jurkat cells (C). The knock-down efficiency 
was further confirmed in HaCaT (B) and Jurkat cells (D), after four weeks of culture. 
Transcript levels were quantified using the housekeeping PPIA gene as an endogenous 











5.5 Cell cycle analysis of CDKAL1 knock-down cells 
The fact that CDKAL1 lies in a chromosome region that is amplified in bladder tumours 
(Oeggerli, Schraml et al. 2006) suggests the possibility that the gene may be involved in 
the control of cell cycle progression. To explore this hypothesis, the effect of CDKAL1 
knock-down on cell proliferation was examined. In particular, the proliferation rates of 
HaCaT clones sh-A11-5 and sh-H6-2 were assessed at several time-points, using the 
WST-8 cell viability assay. A significant decrease in proliferation was observed in the 
knock-down cell lines, as early as one hour after the addition of the detection reagent 
(Fig. 5.5.1). This finding was further investigated by using flow cytometry to assess the 
DNA content of sh-A11-3 and sh-H6-3CDKAL1 knock-down cells. As shown in Figure 
5.5.2, an increase in the percentage of cells in G0/G1, accompanied by a decrease of 
those in S phase, was observed in the CDKAL1 knock-down clones. 









 Figure 5.5.1: CDKAL1 knock-down affects cell proliferation 
CDKAL1 silencing results in a marked, time-dependent decrease in cell proliferation. 
Significance values were calculated using a two-way ANOVA test. Error bars refer to 











Figure 5.5.2: CDKAL1 knock-down influences the rate of cell cycle progression 
Panel A: DNA content of stably transduced HaCaT cells. Gates were configured 
manually in order to determine the percentage of cells in G0/G1, S and G2/M phase, 
based on DNA content. An increase in the percentage of cells in G0/G1, accompanied by 
a decrease of those in S phase, was observed in the CDKAL1 knock-down clones. Panel 








5.6 Expression profiling of CDKAL1 knock-down cells 
Gene expression profiles were generated by comparing the transcriptome of HaCaT 
knock-down lines sh-A11-3, sh-A11-5, sh-H6-2 and sh-H6-3 with that of sh-non-sil-
HaCaT-3 and sh-non-sil-HaCaT-4. 
Two lists of differentially expressed genes were created by comparing: i) the two sh-
A11 vs. the two HaCaT-non-sil. clones (822 transcripts; FDR  0.062), ii) the two sh-
H6 vs. the two HaCaT-non-sil. clones (796 transcripts; FDR  0.01). The combined list 
included 1,342 genes potentially influenced by CDKAL1 knock-down. In order to 
control for transcriptional variation between the two knock-down clones, subsequent 
analyses focused on the subset of genes (n = 276) that were differentially expressed in 
both cell lines. An examination of fold change log ratios showed that 274 out of the 276 
differentially expressed genes followed the same trend in both knock-down clones (Fig. 
5.6.1). Next, two lists, respectively including 118 up- and 156 down-regulated genes 
were generated, and a gene ontology analysis was performed, in order to identify the 
cellular pathways that were most affected by CDKAL1 knock-down. This showed that 
the down-regulated genes were mainly involved in amino acid metabolism, cell 
adhesion, apoptosis and inflammatory processes. Conversely, the up-regulated genes 
were linked to pathways related to metabolism, transcription, cell adhesion, remodelling 
and cell cycle (Fig. 5.6.2).  
In order to identify the genes that were most suitable for follow-up, three transcript sets 
were combined: i) the top 8 up-regulated genes, selected by the GeneGo software, based 
on their differential expression and their involvement in known cellular pathways; ii) 
the top 16 down-regulated genes, selected by the GeneGo software, based on their 
differential expression and their involvement in known cellular pathways; iii) a 
manually curated gene selection, including the ten transcripts associated with the most 
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significant p values and expression fold changes. The use of these selection criteria 
yielded a panel of 14 candidate genes, to be examined in follow-up studies (Fig. 5.6.3 



















 Figure 5.6.1: Graphic representation of the fold change log ratios for the 276 
differentially expressed genes detected by transcription profiling of CDKAL1 
knock-down clones 
The plot shows a high correlation between the fold change log ratios detected in the two 
sets of CDKAL1 knock-down cell lines. The only two genes that show a different trend 
















Figure 5.6.2: GeneGo pathway analysis of the differentially expressed genes 
detected by expression profiling of CDKAL1 knock-down clones 
Panel A: the top ten pathways identified through the analysis of the down-regulated 
gene list. Panel B: the top ten pathways identified through the analysis of the up-
regulated gene list. Maps represent contained sets of experimentally validated 














Figure 5.6.3: Schematic representation of the process leading to the selection of 14 

















log ratio p value Function of gene product * 
GCLM 2.758 0.004 
An enzyme that contributes to 
glutathione biosynthesis. 
 
TUBB2C 2.663 0.0008 
Microtubule constituent protein, 
which also binds GTP. 
 
RPL29 2.633 5.22 x 10-7 Ribosomal protein.  
SEPX1 2.483 4.19 x 10-6 
Selenoprotein with methionine 
sulfoxide reductase activity. 
 
POLR2L 2.44 1.68 x 10-7 RNA polymerase II subunit.  
RPL36A 2.408 1.09 x 10-5 Ribosomal protein.  
GTF2H5 2.043 1.14 x 10-8 
Subunit of the transcription/repair 
factor TFIIH. 
 
NME1 1.772 9.52 x 10-8 
The RNA component of RNase 
MRP (RNase mitochondrial RNA 
processing), which is required for 
pre-rRNA processing and is 
essential for cell viability. 
 
LSM10 1.714 2.90 x 10-9 
A protein consitutent of the U7 
snRNP complex that is involved in 
histone 3'-end processing. It is 
required for cell cycle progression 
from G1 to S phase. 
 











log ratio p value Function of gene product * 
INHBE -5.635 1.62 x 10-7
A member of the activin beta 
family playing a role in pancreatic 
cell growth and proliferation. 
 
TRIB3  -4.029 7.70 x 10-9
A negative regulator of NF-țB and 
AKT1 signalling. 
 
RIMS3 -3.482 9.19 x 10-8
A protein involved in the 
regulation of synaptic membrane 
exocytosis. 
 
DDIT3 -2.638 1.82 x 10-8
A protein inhibiting the DNA-
binding activity of the C/EBP and 
LAP transcription factors. 
 
RAB3GAP1 -1.616 6.39 x 10-8
Catalytic subunit of the RAB3 
GTPase activating protein. 
 
















5.7 Follow-up of differentially expressed genes 
In order to validate the differential expression of the 14 genes selected for follow-up, 
real-time PCRs were carried out in a panel of six knock-down clones, including the four 
that had been used in the microarray experiment (sh-A11-3; sh-A11-5; sh-H6-2 and sh-
H6-3) and two additional lines (sh-A11-2 and sh-H6-1) identified during the screening 
of tGFP-expressing clones (Table 5.4.2). As shown in Figure 5.7.1, the trend in mRNA 
expression was confirmed for 13 out of the 14 genes examined.  
These genes were further investigated by real-time PCR analysis of two knock-down 
Jurkat clones (sh-H6-7-C and sh-H6-8-D). As shown in Figure 5.7.2, the differential 
expression of the selected transcripts was not replicated in this cell type. 
Finally, the disease relevance of the 13 genes was investigated by querying the psoriasis 
transcriptome dataset generated by the CASP consortium (Nair, Duffin et al. 2009). 
Gene expression data was available for 37 pairs of lesional and non-lesional patient skin 
biopsies and for 34 control samples, obtained from unaffected individuals. The analysis 
of this resource revealed two main gene clusters, defined according to the intensity of 
gene expression in the three sample classes (Fig. 5.7.3). Of note, evidence for over-
expression in lesional skin was observed for 11 out of the 13 examined transcripts (all 













Figure 5.7.1: Follow-up of the differentially expressed genes identified by 
microarray analysis (HaCaT cells) 
Transcript levels were quantified in six stably transduced HaCaT clones. All data were 
normalised to the ratio of PPIA and RPLPO expression. Panel A: real-time PCR 
analysis of the five down-regulated genes. Panel B: real-time PCR analysis of the nine 




























Figure 5.7.2: Follow-up of the differentially expressed genes identified by 
microarray analysis (Jurkat cells) 
Transcript levels were quantified in two stably transduced Jurkat clones. All data were 
normalised to the ratio of PPIA and RPLPO expression. Panel A: real-time PCR 
analysis of the four validated down-regulated genes. Panel B: real-time PCR analysis of 
the nine validated up-regulated genes. Error bars refer to technical triplicates in real-
















Figure 5.7.3: Hierarchical clustering analysis of CASP array data for the 13 
differentially expressed genes 
The genes were clustered in two groups, based on similarity in their expression profiles. 
The z-scores calculated for each gene are represented by colour intensities, as shown in 
the top left panel. N: normal skin samples obtained from unaffected individuals; PL: 
perilesional skin samples obtained from psoriatic patients; L: lesional skin samples 






















The aim of these experiments was to explore the function of CDKAL1, with a view to 
understanding the mechanisms through which the gene contributes to disease 
susceptibility. The first phase of the study consisted of a series of bioinformatic 
searches. These indicated that CDKAL1 contains three highly conserved domains (a N-
terminal MTTase motif, a central SAM and a C-terminal TRAM domain), which are 
typically found in proteins encoded by the methylthiotransferase (MTTase) gene family. 
These enzymes, which participate to the modification of tRNAs for ANN codons, can 
be further classified into five subfamilies (MiaB, RimO, MtaB, e-MtaB and MTL1) 
encoded by eukaryote and/or bacterial genomes. Bioinformatic analyses and functional 
assays have demonstrated that CDKAL1 belongs to the e-MtaB subfamily, which is 
found in higher eukaryotes and archaebacteria (Arragain, Handelman et al. 2010). 
The next step in this work was the generation of the laboratory reagents required to 
investigate CDKAL1 function at the experimental level. First, the specificity of a 
commercial Į-CDKAL1 antibody was validated by assessing its ability to bind a 
recombinant GST-CDKAL1 protein and by carrying out western blot experiments in 
cells where the gene had been silenced by transient RNAi. Next, a panel of CDKAL1 
knock-down cells was generated by stable transduction of immortalized keratinocyte 
(HaCaT) and T lymphocyte (Jurkat) cell lines. These cell types were selected since they 
play a major role in the pathogenesis of psoriasis.  
The characterization of the specificity of the Į-CDKAL1 antibody and the generation of 
the stable CDKAL1 knock-down cell lines allowed preliminary functional studies to be 
performed. The antibody was used in western blot and immunofluorescence 
experiments aimed at defining CDKAL1 subcellular localization. The results obtained 
with both approaches demonstrated that CDKAL1 is only found in the cell cytoplasm. 
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This is consistent with recently published data, showing that CDKAL1 localizes to the 
endoplasmic reticulum (ER) (Ohara-Imaizumi, Yoshida et al. 2010). 
Previous studies have shown that CDKAL1 lies in a chromosome region that is 
amplified in bladder tumours (Oeggerli, Schraml et al. 2006), suggesting the possibility 
that the gene may be involved in the control of cell cycle progression. To further explore 
this hypothesis, two independent assays were carried out in CDKAL1 knock-down 
HaCaT cells. The WST-8 cell viability assay measures the activity of a mitochondrial 
dehydrogenase that is mostly functional when cells are proliferating. Conversely, PI 
staining determines the percentage of dividing cells within a given population, by 
measuring their DNA content. The results of both experiments support the notion that 
CDKAL1 may contribute to the regulation of cell cycle progression and cell 
proliferation. In fact, the WST-8 assay showed that CDKAL1 silencing results in a 
marked, time-dependent decrease in cell proliferation. At the same time, PI staining 
showed that CDKAL1 knock-down induces growth arrest by increasing the proportion 
of cells in G0/G1 phase and decreasing the proportion of those in S phase.  
To further investigate CDKAL1 function, the expression profile of HaCaT knock-down 
cells was investigated by means of microarray analysis. To minimize the effects of 
clonal variability and sh-RNA sequence, the experiment was conducted on four 
independent clones, which had been transduced with two distinct sh-RNAs. The 
analysis of transcript levels yielded a panel of 14 candidate genes, potentially influenced 
by CDKAL1 knock-down. Real-time PCR experiments, carried out in a total of six 
independent clones, subsequently validated the differential expression of 13 transcripts. 
An overview of these genes showed that the up-regulated transcripts mostly code for 
housekeeping proteins involved in the maintenance of cellular metabolism. Conversely, 
the down-regulated transcripts appear to participate in inflammatory processes. For 
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instance, TRIB3 contributes to the regulation of NF-NB signalling by inhibiting the 
phosphorylation of its p65 subunit (Wu, Xu et al. 2003). Moreover TRIB3, DDIT3 and 
INHBE all have a role in the unfolded protein response (Ohoka, Yoshii et al. 2005; 
Dombroski, Nayak et al. 2010), an ER-stress induced transcriptional program, which 
has been repeatedly linked to the onset of inflammation in T2D (Hotamisligil 2010) and 
CD (Kaser, Lee et al. 2008). Interestingly, a further down-regulated gene (RIMS3) has 
been implicated in molecular pathways associated with Ca2+ metabolism (Wang, Sugita 
et al. 2000). This is of some relevance, as it has been demonstrated that Ca2+ plays a 
critical role in regulating insulin release through the ATP cycle (Hughes, Lee et al. 
2006). Moreover, a recent publication has shown that CDKAL1 knock-down results in 
impaired insulin release and that this effect is mediated by an alteration of Ca2+ levels, 
due to reduced ATP generation (Ohara-Imaizumi, Yoshida et al. 2010).  
The 13 genes that were differentially expressed in HaCaT cells were further investigated 
in CDKAL1 knock-down Jurkat clones. Real-time PCR analysis of two independent cell 
lines failed to identify any evidence of differential expression for any of the examined 
genes. This discrepancy is likely to reflect the biological diversity of keratinocyte and T 
lymphocytes cell lines. In fact, a search of the BioGPS gene annotation portal (Wu, 
Orozco et al. 2009) revealed that T cells, unlike keratinocytes, express very low levels 
of the 13 critical genes. An additional aspect that needs to be considered is the lower 
knock-down efficiency of CDKAL1 in Jurkat cell lines. Indeed, the 60% knock-down 
observed in these cells may not be sufficient to abolish CDKAL1 function and affect the 
expression of downstream genes.  
In the final phase of the study, the pathogenic relevance of the 13 differentially 
expressed genes was investigated by interrogating a publicly available transcriptome 
dataset. This led to the identification, of two clusters of transcripts sharing similar 
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expression profiles, an observation that further supports the existence of a functional 
connection between the differentially expressed genes. Eleven out of the 13 examined 
genes appeared to be over-expressed in lesional psoriatic skin, whereas two (RPL36A 
and DDIT3) were found to be down-regulated. These findings confirm the notion that 
the genes identified in this study are of genuine relevance to the pathogenesis of 
psoriasis.  
Taken together, the results presented in this chapter indicate that CDKAL1 is involved in 
a variety of cellular pathways, ranging from the maintenance of housekeeping functions 
(e.g. the post-transcriptional modification of tRNAs) to the orchestration of complex 
responses to environmental stimuli (e.g. the regulation of NF-NB signalling). In this 
context, CDKAL1 is likely to contribute to disease onset, by disrupting cell cycle 
progression and inflammatory responses. Defining the mechanisms mediating these 


















Chapter 6: Discussion 
The existence of shared genetic determinants contributing to the pathogenesis of  
multiple inflammatory disorders has been documented by the results of several GWASs 
(Seldin and Amos 2009). Thus, genetic studies are not only identifying novel disease 
pathways, but also uncovering unexpected connections between clinically distinct 
disorders (The Wellcome Trust Case-Control Consortium 2007). In this context, the aim 
of this project was to specifically investigate the genetic overlap between CD and 
psoriasis.  
The notion that a number of shared genetic determinants may contribute to the 
pathogenesis of both conditions is supported by several lines of evidence. First of all, 
clinical observations suggest that individuals affected by CD may be at higher risk of 
developing psoriasis, compared to the general population (Najarian and Gottlieb 2003; 
Christophers 2007). Secondly, CD and psoriasis share some important immuno-
pathogenic features, as both are caused by chronic inflammation of epithelial tissues, 
driven by IFN-J producing Th1 cells and IL-17 producing Th17 cells (Di Cesare, Di 
Meglio et al. 2009; Strober and Fuss 2011). Finally, evidence for a genetic overlap 
between psoriasis and CD emerged from GWASs carried out before the onset of this 
study with SNPs in the IL12B and IL23R genes found to be significantly associated with 
both conditions (Duerr, Taylor et al. 2006; Capon, Di Meglio et al. 2007; Cargill, 
Schrodi et al. 2007; Barrett, Hansoul et al. 2008). In keeping with these results, a 
biologic drug targeting the protein encoded by IL12B has been found to be effective in 
the treatment of both CD and psoriasis (Toichi, Torres et al. 2006; Leonardi, Kimball et 
al. 2008; Papp, Langley et al. 2008; Ryan, Thrash et al. 2010). 
To test the hypothesis that further CD markers may contribute to psoriasis susceptibility, 
a total of 26 CD loci were analysed in a sizeable case-control dataset. This led to the 
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identification of a novel disease association for a variant lying in intron 5 of the 
CDKAL1 gene, a finding that was subsequently replicated in an independently 
ascertained dataset of North-American origin. Since these results were obtained, a 
number of psoriasis GWASs have been carried out (Zhang, Huang et al. 2009; 
Ellinghaus, Ellinghaus et al. 2010; Huffmeier, Uebe et al. 2010; Strange, Capon et al. 
2010; Stuart, Nair et al. 2010; Sun, Cheng et al. 2010), but none has reported the 
identification of disease associated CDKAL1 variants. This may reflect the experimental 
design of these studies, where only variants that exceed a given significance threshold 
in the discovery dataset are followed-up in replication samples. In fact, the GWAS 
carried out by Strange et al. (Strange, Capon et al. 2010) identified a disease association 
with a CDKAL1 marker (rs7748720), but the statistical significance of this finding (P = 
6.3 x 10- 4) was not deemed sufficient to warrant a replication effort. 
Of note, the GWAS carried out by Strange et al. (Strange, Capon et al. 2010) identified 
psoriasis associated alleles within the REL and TYK2 genes (Strange, Capon et al. 
2010), both of which are well known genetic determinants for CD (Franke, McGovern 
et al. 2010). Thus, a total of five CD genes have now been implicated in psoriasis 
susceptibility (IL12B, IL23R, CDKAL1, REL and TYK2), with more likely to emerge 
from an ongoing meta-analysis of two large studies (Strange, Capon et al. 2010; Stuart, 
Nair et al. 2010). Interestingly, TYK2 encodes a protein kinase that mediates the 
signalling activity of the IL-23 receptor complex (Oyamada, Ikebe et al. 2009). The 
presence of associations at this locus further demonstrates that IL-23 driven activation 
of Th17 lymphocytes is the key pathogenic pathway shared by psoriasis and CD. 
The CDKAL1 SNP that has been associated with CD and psoriasis is completely 
independent from the markers conferring T2D susceptibility. Thus, CDKAL1 must 
harbour two unrelated disease alleles. Although the pattern of LD conservation around 
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the critical SNPs indicates that both causal variants must lie within intron 5, their 
localization has not been refined any further. The use of the Immunochip array, which 
affords substantial coverage across the CDKAL1 gene region, is expected to address this 
issue, as extended patients cohorts are currently being typed on this platform. Although 
these studies are likely to reduce the list of candidate susceptibility alleles to a small 
number of markers, the analysis non-coding SNPs associated with other common 
diseases suggests that the characterization of causal variants will be a challenging task, 
requiring the functional dissection of long-range cis-regulatory elements (Meyer, Maia 
et al. 2008; Wasserman, Aneas et al. 2010).  
Despite the fact that the pathogenic involvement of CDKAL1 is very well replicated 
(Saxena, Voight et al. 2007; Scott, Mohlke et al. 2007; Steinthorsdottir, Thorleifsson et 
al. 2007; The Wellcome Trust Case-Control Consortium 2007; Zeggini, Weedon et al. 
2007; Barrett, Hansoul et al. 2008; Franke, McGovern et al. 2010; McGovern, Jones et 
al. 2010), the gene expression pattern has not been comprehensively investigated, with 
most studies focusing on the tissues that are affected by T2D (e.g. pancreas and skeletal 
muscle). Here, the analysis of CDKAL1 expression has been extended to include a much 
wider range of cell types. This showed that CDKAL1 transcripts are highly expressed in 
CD4+ T cells but become down-regulated upon lymphocyte activation. The nature of the 
samples used in these experiments (pooled cDNAs obtained from cells stimulated with 
unspecific mitogen agents) precludes any particular speculation on the role of CDKAL1 
in lymphocyte activation. Further studies focusing on specific cell sub-populations (e.g. 
naïve vs. in-vitro differentiated T helper lymphocytes) and stimuli (e.g. direct activation 
of the T cell receptor) will enable researchers to address this issue, which is of 
considerable relevance, given the key role of CD4+ T lymphocytes in the pathogenesis 
of psoriasis and CD. 
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The function of the CDKAL1 protein has also been the subject of little experimental 
investigation. Thus, the first step of the functional analyses reported in this thesis was 
the validation of appropriate laboratory reagents. The specificity of a commercial anti-
CDKAL1 polyclonal antibody was validated, allowing the implementation of western 
blot and immunofluorescence protocols. These are fundamental applications, which, in 
the case of CDKAL1 have provided important information on the protein expression 
levels and subcellular localization. Further work will now be required to optimize the 
use of this antibody for other, equally important applications. For instance, the 
development of a protocol for immuno-histochemistry would be of particular interest, as 
it would allow researchers to investigate CDKAL1 expression in the tissues of patients 
affected by psoriasis, CD or T2D.  
Another key reagent that has been generated in this study is a set of stable CDKAL1 
knock-down cells. The preliminary characterization of four indepenedent clones has 
generated some insights into the possible function of CDKAL1, as the results of 
transcriptome analyses suggested that the gene may be involved in the regulation of NF-
țB mediated responses (through an effect on TRIB3) and Ca2+ metabolism (through an 
effect on RIMS3). The role of NF-NB signalling in the pathogenesis of chronic 
inflammation is well established (Barnes and Karin 1997; Hayden and Ghosh 2008) as 
is the link between Ca2+ signalling and cell proliferation (Roderick and Cook 2008). 
Thus, it is tempting to speculate that the dysregulation of the above pathways might be 
the mechanism whereby CDKAL1 confers susceptibility to clinically distinct disorders. 
This pathogenic model can now be used to inform the design of further hypothesis-
driven experiments (e.g. investigations of NF-NB signalling disruptions). Such studies 
could be carried out in the HaCaT cell lines described here, but also in knock-down 
clones derived from cell types that may have further relevance to the pathogenesis of 
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CD (e.g. the enterocyte-like Caco-2 human intestinal cell line) or T2D (e.g. the BxPC-3 
human pancreatic cancer cell line). Cell lines stably over-expressing CDKAL1 could 
also be generated and used to validate the findings obtained in knock-down systems.  
Clearly, an in-depth investigation of CDKAL1 function would require the establishment 
of an in-vivo knockout model. Of note a Cdkal1 -/- mouse has been generated (Ohara-
Imaizumi, Yoshida et al. 2010), but its phenotypic characterization has been restricted to 
the analysis of beta-pancreatic cells. Given the involvement of CDKAL1 in other organ-
specific pathologies, the analysis of other tissues and cell types would certainly be of 
considerable interest. 
Taken together these results presented in this thesis show that the integration of large-
scale association studies and in-vitro knockout technology has the potential to offer 
novel insights into pathogenetic processes. At the same time, the preliminary nature of 
the functional findings presented here underscores the arduous nature of the work that is 
necessary to translate the results of genetic studies into a detailed understanding of the 
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Background: Psoriasis is an immune-mediated skin
disorder that is inherited as a multifactorial trait. Linkage
analyses have clearly mapped a primary disease
susceptibility locus to the major histocompatibility
complex (MHC) region on chromosome 6p21. More
recently, whole-genome association studies have identi-
fied two non-MHC disease genes (IL12B and IL23R),
both of which also confer susceptibility to Crohn disease
(CD).
Objective and methods: To ascertain the genetic
overlap between these two inflammatory conditions
further, we investigated 15 CD-associated loci in a
psoriasis case–control dataset.
Results: The analysis of 1256 patients and 2938
unrelated controls found significant associations for
loci mapping to chromosomes 1q24 (rs12035082,
p= 0.009), 6p22 (rs6908425, p= 0.00015) and
21q22 (rs2836754, p= 0.0003). Notably, the marker
showing the strongest phenotypic effect (rs6908425)
maps to CDKAL1, a gene also associated with type 2
diabetes.
Conclusions: These results substantiate emerging
evidence for a pleiotropic role for s genes that
contribute to the pathogenesis of immune-mediated
disorders.
Psoriasis is a chronic, immune-mediated skin
disorder that affects up to 4% of the population.1
Familial recurrence of the disease is well docu-
mented, and psoriasis has long been regarded as a
multifactorial trait. Linkage studies have repeat-
edly identified a primary disease susceptibility
locus (PSORS1), lying within the major histocom-
patibility complex (MHC) on chromosome 6p21.2
Several putative non-MHC loci with smaller
effects (PSORS2–10) have also been described.3
These regions tend to overlap with genomic
intervals conferring susceptibility to other inflam-
matory conditions, notably Crohn disease (CD).4 5
The observation of an increased incidence of
psoriasis among patients with CD6 is consistent
with these findings and suggests the existence of
genetic determinants predisposing to both inflam-
matory conditions. We and others have previously
shown that CD-associated sequence variants in the
IL23R and IL12B genes confer a significant increase
in psoriasis risk.7 8 In this study, we investigated
the contribution of CD genetic determinants
to psoriasis susceptibility. We assessed 15 CD
susceptibility loci recently identified by genome-
wide association analysis, and identified three




In total, 1256 patients (645 male and 611 female
patients) were recruited within the UK through St
John’s Institute of Dermatology, London (n=638),
Glasgow Western Infirmary (n=211) and the
Dermatology Centre, University of Manchester
(n=407). All patients were of north European
descent and had early-onset (occurring before
40 years of age) psoriasis vulgaris. Less than 1%
of the patients (n=8) also had CD. These patients
were matched with 2938 controls (1488 male, 1450
female patients), previously analysed by the
Wellcome Trust Case–Control Consortium
(WTCCC).9 All patients and controls gave
informed consent for the use of their DNA in
genetic epidemiology analyses. The study was
approved by the Guy’s and St Thomas’ Hospitals
Ethics Committee of Kings College London, the
Salford and Trafford Local Research Ethics
Committee and North Glasgow University
Hospitals NHS Trust Local Research Ethics
Committee.
Genotyping and statistical analyses
Patients were typed using TaqMan assays (Applied
Biosystems, Foster City, California, USA). Control
genotypes were obtained from publicly released data
(available at www.wtccc.org.uk/info/summary_
stats.shtml). The allele frequencies of cases and
controls were compared using a x2 test with one
degree of freedom, after confirming that the geno-
type distributions did not deviate from Hardy–
Weinberg equilibrium (p.0.05). Regression analysis
was carried out using PLINK software.10
RESULTS
We examined 15 SNPs that had been associated
with CD susceptibility in the WTCCC scan9 and
its follow-up study,11 based on the observation of p
values ,1025. We did not analyse any single-
nucleotide polymorphism (SNP) from the
CARD15/NOD2 locus, as we had previously shown
that psoriasis is not associated with sequence
variants in this gene.12 We also excluded chromo-
some 6p21 markers from our study, as linkage
disequilibrium with PSORS1 alleles would have
confounded the interpretation of association sig-
nals.
We performed association analyses by compar-
ing the allele frequencies of our patients with those
of the WTCCC controls. We applied an assump-
tion that cases could be matched with controls
that had been typed on a different platform (the
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Affymetrix 500 K array set), having shown a 99.7% concordance
rate between the WTCCC genotypes and those generated by
Taqman assays.11
Following x2 analysis, we observed significant disease associa-
tions for three independent markers rs12035082 (p=0.009;
OR=1.14; 95% CI 1.03 to 1.25), rs6908425 (p=0.00015;
OR=1.26; 95% CI 1.12 to 1.42) and rs2836754 (p=0.0003;
OR=1.17; 95% CI 1.06 to 1.30). We also found an association of
marginal significance for SNP rs1000113 (p=0.045; OR=1.20;
95% CI 1.00 to 1.45). In order to address the issue of multiple
testing, we calculated false discovery rates (FDR)13 for the analysis
of 15 SNPs. We found that all three significant associations
surpassed the 5% FDR threshold (p(0.01), with two (rs6908425
and rs2836754) exceeding 1% FDR (p,0.001).
We next carried out logistic regression analysis, using age and
sex as specific covariates. This confirmed that the significance of
our association results was not affected by either of these
variables.
In order to assess the presence of epistasis between the
various disease-associated alleles, we implemented a case-only
test for the detection of gene–gene interaction.14 Under the null
hypothesis of no interaction, the genotype frequencies of
unlinked markers are expected to be independent from each
other. We therefore analysed the distribution of patient
genotypes by carrying out x2 tests on standard contingency
tables. We observed non-significant x2 values for all pair-wise
comparisons between disease-associated SNPs (rs12035082 v
rs6908425; rs12035082 v rs2836754; rs6908425 v rs2836754). We
used the same approach to test for interactions with HLA-
Cw*0602, the strongest determinant of disease risk from the
PSORS1 locus. The p values for the HLA-C v rs6908425 and
HLA-C v rs2836754 comparisons were non-significant, but the
HLA-C v rs12035082 analysis generated suggestive evidence for
an interaction between the two loci (p=0.02).
DISCUSSION
The existence of shared genetic determinants between psoriasis
and CD is clearly documented, with variants in the IL23R and
IL12B genes showing highly significant associations with both
diseases.7 8 With this study we have further investigated the role
of CD genes in psoriasis pathogenesis, by examining a panel of
CD susceptibility loci, recently identified by whole-genome
association analysis. In selecting markers for genotyping, we
used a conservative level of statistical significance (p,1025), as
several studies have demonstrated the merit of following
association signals of this order of magnitude.11 15 16 Our results
further validate this approach, as we were able to document
associations with psoriasis for three of the examined SNPs.
The possibility that our findings are due to population
stratification is unlikely, given that cases and controls have the
same ethnic and geographical origin. Moreover, the regional
variation data generated by the WTCCC (available at http://
www.b58cgene.sgul.ac.uk/) show that the allele frequencies of
SNPs rs12035082, rs6908425 and rs2836754 are homogeneous
across the UK, ruling out the possibility that the association is
due to hidden population structure.
As our study is based on the same set of controls that allowed
the identification of CD susceptibility genes in the WTCCC
association scan, we cannot formally exclude the possibility
that the similarity of findings may reflect a control sampling
effect. However, the fact that the population frequencies of SNP
rs12035082 and rs2836754 have been validated in another UK
sample11 argues against this hypothesis.
Given the multifactorial nature of psoriasis inheritance, we
implemented a series of case-only tests to assess the presence of
epistasis between disease-associated loci. We found suggestive
evidence for an interaction between rs12035082 and HLA-C, a
finding that should be interpreted with caution, given its
marginal significance (p=0.02) and the degree of multiple
testing inherent in interaction analyses. Validation of such a
modest effect will probably require analysis of a substantially
larger patient cohort.
All three disease-associated SNPs map to non-coding regions.
Rs6908425, which lies within intron 5 of the CDKAL1
transcripts, is the only disease-associated SNP found within a
known gene. Although the function of CDKAL1 is unknown,
intron 5 variants have been associated with both type 2
diabetes17 and CD,9 suggesting that the gene may play an
important role in the pathogenesis of both conditions. Given the
high frequency of type 2 diabetes, it is probable that a
significant percentage of our psoriatic patients (5–10%) may
also exhibit diabetes. Although this is undoubtedly a confound-
ing factor, it is unlikely that the results obtained for SNP
rs6908425 simply reflect an association with type 2 diabetes. In
fact, our calculations indicate that a sample including up to 20%
of this patient cohort would have very limited power (,15%)
Table 1 Association analysis results
Marker Chromosome Gene
Minor allele frequency
OR p ValueCases Controls
rs12035082 1q24 – 0.42 (993/2366) 0.39 (2281/5868) 1.14 0.009
rs10801047 1q31 – 0.07 (164/2338) 0.07 (395/5860) 1.04 0.66
rs10210302 2q37 ATG16L1 0.48 (1157/2386) 0.48 (2822/5872) 1.02 0.71
rs9858542 3p21 Many* 0.29 (692/2360) 0.28 (1652/5862) 1.06 0.30
rs17234657 5p13 – 0.13 (319/2448) 0.12 (731/5866) 1.05 0.47
rs6596075 5q23 Many* 0.17 (396/2362) 0.17 (972/5870) 0.98 0.82
rs1000113 5q33 IRGM 0.08 (183/2288) 0.07 (394/5854) 1.20 0.045
rs6908425 6p22 CDKAL1 0.19 (452/2358) 0.23 (1348/5864) 1.26 0.00015
rs6927210 6q23 – 0.50 (1200/2388) 0.48 (2825/5866) 0.92 0.08
rs887822 7q36 – 0.27 (655/2384) 0.29 (1695/5868) 1.07 0.20
rs6601764 10p15 – 0.42 (973/2316) 0.41 (2368/5810) 1.07 0.20
rs10761659 10q21 – 0.47 (1103/2326) 0.46 (2703/5866) 1.05 0.27
rs10883365 10q24 NKX2–3 0.49 (1081/2218) 0.47 (2730/5800) 0.93 0.18
rs2542151 18p11 PTPN2 0.17 (372/2140) 0.16 (957/5870) 1.08 0.25
rs2836754 21q22 – 0.39 (847/2168) 0.35 (2072/5862) 1.17 0.0003
*The associations observed for the 3p21 and 5q23 regions spanned large genomic regions, including multiple genes.
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to detect an association with type 2 diabetes, at the observed
level of significance. An accurate assessment of rs6908425 effect
size will eventually require in-depth clinical characterisation of
psoriatic cohorts, including metabolic analysis. The remaining
disease-associated markers identified in our study map to inter-
genic regions. SNP rs2836754 lies between the NP_001001692 and
C21orf104 anonymous transcripts on chromosome 21q22. SNP
rs12035082 lies in a ‘‘gene desert’’ on chromosome 1q24, within a
77-kb linkage disequilibrium (LD) block. Although the LD block
does not include any known gene, it encompasses several genomic
segments that are highly conserved among mammals and that
may regulate the expression of the downstream TNFSF18 gene.
As TNFSF18 is a mediator of nuclear factor kappa-b signalling and
is a key molecule for the maintenance of immunological self-
tolerance,18 it is interesting to speculate that disease-associated
alleles may confer susceptibility to psoriasis and CD by altering
TNFSF18 expression levels.
In conclusion, we have shown that psoriasis is associated
with sequence variants predisposing to type 2 diabetes and CD.
These observations provide increased support for the existence
of critical, yet pleiotropic loci, conferring susceptibility to
clinically distinct disorders. Further genetic and functional
analyses will now be required to characterise fully the role of
disease-associated variants.
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Key points
c Psoriasis is an inflammatory skin disorder that is inherited as a
multifactorial trait. Previous studies have demonstrated that
two Crohn disease (CD) susceptibility genes (IL23R and IL12B)
are also associated with psoriasis.
c To further investigate the overlap between psoriasis and CD
susceptibility determinants, we examined 15 CD-associated
single-nucleotide polymorphisms (SNPs) in a dataset of1256
psoriatic patients and 2938 controls.
c We found that three of the examined SNPs are significantly
associated with psoriasis. Of note, the marker showing the
strongest phenotypic effect maps to a gene previously
associated with type 2 diabetes. These results provide further
evidence for the existence of pleiotropic genes predisposing to
multiple disorders.
Letter to JMG
116 J Med Genet 2008;45:114–116. doi:10.1136/jmg.2007.053595
 group.bmj.com on November 24, 2010 - Published by jmg.bmj.comDownloaded from 
ORIGINAL ARTICLE
Differential contribution of CDKAL1 variants to psoriasis,
Crohn’s disease and type II diabetes
M Quaranta1, AD Burden2, CEM Griffiths3, J Worthington4, JN Barker1, RC Trembath1 and F Capon1
1King’s College London, Division of Genetics and Molecular Medicine, London, UK; 2Department of Dermatology, University of
Glasgow, Glasgow, UK; 3Department of Dermatology, University of Manchester, Manchester, UK and 4arc Epidemiology Unit,
University of Manchester, Manchester, UK
Psoriasis is an immune-mediated skin disorder, which is inherited as a complex trait. Genome-wide linkage and association
studies have identified a major disease susceptibility locus on chromosome 6p21, as well as a number of genetic determinants
of smaller effect. Our group has also documented a significant association between psoriasis and CDKAL1, a gene previously
implicated in the pathogenesis of Crohn’s disease (CD) and type II diabetes (TIID). With this study, we validate this association,
through the analysis of CDKAL1 single nucleotide polymorphism (SNP) rs6908425 in an independently ascertained psoriasis
dataset (replication sample: 1323 cases vs 1368 controls, P¼ 0.00012, odds ratio (OR): 1.28; combined sample: 2579 cases
vs 4306 controls, P¼ 4" 10#6, OR: 1.26). We also show that the association with psoriasis and CD is completely independent
from that with TIID. Finally, we report the results of expression studies demonstrating that CDKAL1 transcripts are virtually
absent from skin keratinocytes, but are abundantly expressed in immune cells, especially in CD4þ and CD19þ lymphocytes.
It is to be noted that our data indicate that CDKAL1 becomes markedly downregulated when immune cells are activated with
proliferating signals. Taken together, our results document the presence of allelic heterogeneity at the CDKAL1 locus and
suggest that CDKAL1 alleles may confer susceptibility to clinically distinct disorders through differential effects on disease-
specific cell types.
Genes and Immunity (2009) 10, 654–658; doi:10.1038/gene.2009.51; published online 9 July 2009
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Introduction
Psoriasis is a chronic immune-mediated skin disease,
characterized by altered keratinocyte differentiation,
angiogenesis and infiltration of inflammatory elements
(T-lymphocytes, neutrophils and dendritic cells) into the
dermis and the epidermis.1 Familial recurrence of the
disease is well documented, so that psoriasis is widely
regarded as complex genetic trait, resulting from the
interaction between environmental triggers and inher-
ited disease susceptibility alleles.2 Genome-wide linkage
scans have unambiguously mapped a primary disease
susceptibility locus (PSORS1) to the major histocompat-
ibility complex (MHC),3 where refinement studies and
resequencing efforts point to HLA-C as the most likely
PSORS1 candidate.4,5 More recently, the advent of
genome-wide association scans has allowed the identi-
fication of several non-MHC susceptibility genes,
including IL12B, IL23R, RNF114, TNFAIP3, TNIP1, IL4/IL13
and LCE3B/3C6–11 Of these, IL12B and IL23R harbour
variants that also confer susceptibility to Crohn’s disease
(CD)12 and ankylosing spondylitis.13 Similarly, TNFAIP3
alleles have been associated with rheumatoid arthritis,14
systemic lupus erythematosus15 and type I diabetes.16
Similar instances of genes conferring susceptibility to
multiple conditions (for example, PTPN2, IL2RA and IL2)
have emerged from other genome-wide association
scans,17,18 highlighting unexpected connections between
clinically distinct disorders.
In this context, our group has focused on the overlap
between the genetic determinants for psoriasis and CD,
based on the common inflammatory nature of these
conditions, both of which are driven by the infiltration of
CD4þ T-lymphocytes in epithelial tissues. Through the
analysis of a well-characterized case-control resource, we
have previously documented significant associations
between psoriasis and three CD susceptibility alleles,
mapping to chromosomes 1q24, 6p22 and 21q22.19 It is to
be noted that the marker showing the strongest
phenotypic effect is mapped to CDKAL1, a gene also
associated with type II diabetes (TIID).20–22 All three loci
were recently analysed in a North-American cohort and
tentative support was obtained for the CDKAL1 associa-
tion (P¼ 0.06; one-sided P-value: 0.03).23 With this study
we provide significant replication data supporting the
involvement of CDKAL1 in the pathogenesis of psoriasis.
We also show that this association is independent from
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the allele conferring susceptibility to TIID. Finally we
provide real-time PCR data, indicating that CDKAL1 is
strongly expressed in CD4þ T-lymphocytes, a T-cell




The United Kingdom case-control sample analysed in this
study has been described elsewhere.19 Briefly, a total of 962
British patients of North-European descent were recruited
through St John’s Institute of Dermatology, London;
Glasgow Western Infirmary; and the Dermatology Centre,
University of Manchester. All patients were affected by an
early onset of psoriasis vulgaris (disease onset occurring
before 40 years of age). Control genotypes were obtained
by querying the publicly available data generated by the
Wellcome Trust Case-Control Consortium (WTCCC).18
Genotypes from the Collaborative Association Study of
Psoriasis (CASP) were obtained from the Genetic Associa-
tion Information Network (GAIN) Database, through
dbGaP accession number phs000019.v1.p1. Primary
keratinocytes were obtained from the skin of unaffected
individuals, who were undergoing abdominoplasty at
Guy’s and St Thomas Hospital NHS Trust. All patients
and controls gave their informed consent for participating
in this project. The study was approved by the Guy’s and
St Thomas’ Hospitals Ethics Committee, the Salford and
Trafford Local Research Ethics Committee, and North
Glasgow University Hospitals NHS Trust Local Research
Ethics Committee.
Genotyping and direct sequencing
Single nucleotide polymorphism (SNP) rs10946398 was
typed with a TaqMan SNP genotyping assay (Applied
Biosystems, Foster City, CA, USA), run on a 7900HT fast
real-time PCR system (Applied Biosystems). We expect
the error rate for this assay to be less than 1%, as we have
previously shown that our TaqMan genotypes are 99.7%
concordant with those obtained by the WTCCC for the
same markers.19
CDKAL1 RT-PCR products were sequenced with a
BigDye Terminator cycle sequencing kit (Applied Bio-
systems) and loaded on an ABI 3730xl automated
sequencer (Applied Biosystems). The sequence of the
amplified products was compared with that of CDKAL1
full-length cDNA, using Sequencher (Gene Codes
Corporation, Ann Arbor, MI, USA).
Statistical analyses
Genotype quality controls (analysis of call rate and
Hardy–Weinberg equilibrium) and w2-tests were imple-
mented with PLINK. The genotypes of marker rs6908425
were also imputed with PLINK,24 using CDKAL1
HapMap data as a reference and applying the following
QC filters: call rate 490%, MAFX1% and HWE
P-valueX10#4. The value of the INFO metric, which
varies from 0 to 1 and measures the quality of imputed
genotypes, was 0.92. The results of this analysis were
validated with the MACH software,25 which confirmed
the presence of significant association between psoriasis
and imputed rs6908425 genotypes (data not shown).
Meta-analyses of the United Kingdom and CASP
samples were implemented with Review Manager. The
statistical power of the examined datasets was assessed
with Genetic Power Calculator,26 using published allele
frequencies and odds ratios.
Expression studies
Multiple tissues and human blood fractions cDNA
panels were purchased from Clontech (Mountain View,
CA, USA). Both panels contain first-strand cDNA
preparations obtained from pools of tissues/cells. Data
provided by the manufacturer and based on the
immuno-staining of relevant surface markers (CD4,
CD8, CD19, CD25 and CD171), indicate that the purity
of the lymphocyte populations in the blood fraction
panel exceeds 95% for resting cells and 84% for activated
cells.
Primary keratinocytes were grown in Epilife medium
(Invitrogen, Portland, OR, USA) and were treated with
100 ngml#1 of each cytokine (all purchased from R&D
Systems, Minneapolis, MN, USA) at passages 2–4. The
cytokines bioactivity was verified by confirming their
ability to induce the expression of known target genes
(data not shown). About 24 h after cytokine treatment
(5 h for interferon (IFN)-a), cells were harvested, total
RNA was extracted with TRI reagent (Sigma-Aldrich,
St Louis, MO, USA) and cDNA was reverse transcribed
using a Superscript first-strand synthesis kit (Invitrogen).
Transcripts were quantified by using TaqMan gene
expression assays (Applied Biosystems), according to the
manufacturer’s protocol. Briefly, 2ml of cDNA were
amplified in a final volume of 20 ml, in the presence of
primers and probes for CDKAL1 (Applied Biosystems
assay id: Hs00214949_m1), PPIA (house-keeping gene
encoding cyclophilin A; assay id: Hs99999904_m1) or
RPLPO (house-keeping gene encoding large PO riboso-
mal protein; assay id: Hs99999902_m1). All real-time
PCR reactions were carried out in duplicate, using the
following cycling conditions: 15min 951C; (30 s 951C, 1 in
601C)" 40. After amplification, relative CDKAL1 expres-
sion levels were derived using the DDCt method.27
Results
Validation of CDKAL1 association with psoriasis
In the first phase of this study, we sought access to the
data generated by the CASP (an association scan of 1409
patients and 1436 controls of European ancestry10), with
a view to validating the association between psoriasis
and the CD loci on chromosomes 1q24, 6p22 and 21q22.
Good quality SNP genotypes (call rate490%, P-value for
Hardy–Weinberg equilibrium 40.05) were available for
markers rs12035082 (chromosome 1q24) and rs2836754
(chromosome 21q22), in 1323 cases and 1368 controls. As
SNP rs6908425 (chromosome 6p22) was not present in
the Perlegen array used by CASP, genotypes for this
marker were imputed using PLINK. After association
analysis, the CASP results were compared with those of
our original study. As shown in Table 1, CDKAL1 SNP
rs6908425 was the only marker generating convincing
association in both the discovery and the replication
sample. No evidence of heterogeneity was detected
between the United Kingdom and CASP datasets
(P¼ 0.85; I2¼ 0%) and a meta-analysis of the two
studies yielded a P-value of 4" 10#6 (OR: 1.26; 95% CI:
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1.15–1.41). A genotypic analysis of the combined
resource (2579 cases vs 4306 controls) further confirmed
the association between rs6908425 and psoriasis (P-value
for Armitage trend test: 1.4" 10#8).
The CDKAL1 SNP associated with TIID does not confer
susceptibility to psoriasis or CD
The data generated by the HapMap Consortium indicate
that rs6908425 is not correlated with the CDKAL1
markers that have been associated with TIID
(rs10946398, rs9465871, rs7767391; r2p0.04 for all),
suggesting that the two association signals are comple-
tely independent. This does not exclude the possibility
that TIID associated SNPs may confer susceptibility to
psoriasis, independently from rs6908425. To explore this
hypothesis, we analysed the SNP yielding the strongest
association with TIID (rs10946398), in 962 United King-
dom psoriatic cases and 2938 unrelated controls. We also
examined the data generated by the CASP study for SNP
rs9460546 (r2 with rs10946398: 1.0). Although our
calculations indicated that the statistical power of the
combined dataset exceeded 90%, we failed to detect any
significant association between rs10943698 and psoriasis
(P¼ 0.60). We next queried the data generated by the
Wellcome Trust Case Control Consortium,18 to assess
whether rs10943698 was associated with CD. Once more,
the analysis of a sizeable resource (1747 cases and 2938
controls) failed to generate any evidence for association
(P¼ 0.84). Taken together, these data document the
presence of allelic heterogeneity at the CDKAL1 locus,
where rs6908425 shows an association with psoriasis and
CD that is completely independent from that between
rs10946398 and TIID.
CDKAL1 transcripts are virtually absent from skin
keratinocytes, but are clearly expressed in immune cells
The function of the CDKAL1 protein is currently
unknown and only limited information is available on
CDKAL1 gene expression, as previous studies have
mostly focused on tissues, which are relevant to the
pathogenesis of diabetes.20,22 We therefore carried out a
comprehensive analysis of CDKAL1 transcript levels, by
real-time PCR analysis of cDNAs from 20 tissues and cell
types. In agreement with published data, we observed
strong CDKAL1 expression in skeletal muscle and
weaker signals in the pancreas, the liver and the kidney
(Figure 1). Surprisingly, very low transcript levels were
observed in some of the tissues affected by CD (the small
intestine and the colon) and psoriasis (skin keratino-
cytes). Conversely, CDKAL1 was abundantly expressed
in immune cells, with the strongest signal seen in CD4þ
T-lymphocytes and CD19þ B-lymphocytes (Figure 1).
The information available on the Ensembl genome
browser indicates the existence of four CDKAL1 tran-
script isoforms (the full length cDNA, two transcripts
lacking portions of the gene untranslated regions and a
shorter cDNA lacking exons 4 and 13), which can all be
detected by the exon 10 probe used for our real-time PCR
Table 1 Association analysis of 1q24, 6p22 and 21q22 CD loci in two psoriasis datasets
Marker (chromosome) Gene Discovery sample
(1256 cases vs. 2938 controls)
CASP sample
(1323 cases vs 1368 controls)
Combined sample













rs12035082 (1q24) — 0.42 0.39 0.009 0.40 0.41 0.58 0.05 1.07 (1.00–1.15) —
rs6908425 (6p22) CDKAL1 0.19 0.23 0.00015 0.20 0.24 0.00012 4" 10#6 1.26 (1.15–1.41) C
rs2836754 (21q22) FLJ45139 0.39 0.35 0.0003 0.39 0.36 0.06 0.001 1.15 (1.06–1.25) —
Abbreviations: CASP, Collaborative Association Study of Psoriasis; CD, Crohn’s disease; CI, confidence interval; MAF, minor allele frequency.















































































































Figure 1 Real-time PCR analysis of CDKAL1 gene expression.
Top panel: Transcript levels were quantified in 20 tissues and cell
types, using the expression of PPIA as an internal control. The
CDKAL1/PPIA ratio for the brain was set as a baseline value, to
which all transcript levels were normalized. Skel. Muscle: skeletal
muscle; small intest: small intestine; CD4þ : CD4þ T-lymphocytes;
CD8þ : CD8þ T-lymphocytes; CD19þ : CD19þ B-lymphocytes.
Bottom panel: Transcript levels were quantified in cDNAs obtained
from pools of resting and activated lymphocytes, using the
expression of PPIA as an internal control. The CDKAL1/PPIA ratio
for CD4þ T-lymphocytes was set as a baseline value, to which all
transcript levels were normalized. Error bars refer to technical
duplicates in real-time PCR experiments. CD4þ : resting CD4þ
T-lymphocytes; Ac CD4þ : activated CD4þ T-lymphocytes;
CD8þ : resting CD8þ T-lymphocytes; Ac CD8þ : activated
CD8þ T-lymphocytes; CD19þ : resting CD19þ B-lymphocytes;
Ac CD19þ : activated CD19þ B-lymphocytes. *Po0.05; **Po0.01.
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experiments. To determine whether our expression
analysis had detected the full-length CDKAL1 transcript,
the isoform lacking exons 4 and 13, or both, we designed
RT-PCR primers that would amplify both transcripts, by
annealing to exons 1 and 16. After electrophoresis of RT-
PCR products, we consistently observed a single ampli-
fication band, whose molecular weight and sequence
matched those of the full-length CDKAL1 transcript
(Supplementary Figure 1). This led us to conclude that
the short CDKAL1 isoform was not expressed in any of
the examined tissues, so that the real-time PCR signals
we had previously observed were because of the
presence of transcripts that included all of the CDKAL1
coding exons.
Given the fundamental role played by lymphocytes
and keratinocytes in the pathogenesis of psoriasis, we
decided to further investigate CDKAL1 expression in
these cell types. We first analysed cDNA from primary
keratinocytes obtained from healthy donors and treated
with a panel of pro-inflammatory cytokines (IFNa, IFNg,
TNFa, IL-17, IL-22 and IL-23), to assess whether any of
these molecules could induce CDKAL1 gene expression.
We failed to observe up-regulation of gene expression by
any of these cytokines (Supplementary Figure 2).
We next focused our attention on lymphocytes and
carried out real-time PCR analyses of T- and B-cells that
had been activated, with well-characterized mitogens
(concavalin A for CD4þ lymphocytes, phytohaemoag-
glutinin for CD8þ lymphocytes and pokeweed mitogen
for CD19þ lymphocytes, all used for 72 h). The
comparison with resting cells showed that CDKAL1 is
markedly downregulated in CD4þ , CD8þ and CD19þ
proliferating lymphocytes (Figure 1). To exclude the
possibility that these data might reflect a differential
expression of the housekeeping gene (PPIA) in stimu-
lated vs non-stimulated cells, we also measured the
transcription of RPLPO (ribosomal protein, large PO)
mRNA. The amplification of this additional reference
gene confirmed our previous results, indicating that
CDKAL1 is genuinely downregulated in proliferating
lymphocytes (Supplementary Figure 3).
Discussion
The identification of shared genetic determinants for
clinically distinct disorders is an emerging theme under-
lying the results of recent genome-wide association
scans.28 With this study, we sought to dissect the
molecular genetic basis of one such observation of
overlap between disease susceptibility loci. CDKAL1
was identified as a putative susceptibility gene for TIID
and CD by the Wellcome Trust Case Control Consor-
tium.18 Both associations were extensively replicated by
follow-up studies,20,22,29 independent scans21 and ana-
lyses of related phenotypes (for example, pancreatic
b-cell function for TIID30 and ulcerative colitis for CD31).
Our group subsequently identified a significant associa-
tion between CDKAL1 and psoriasis, in a sizeable cohort
of British descent.19 Here, we provide an independent
validation for CDKAL1 involvement in psoriasis, through
the analysis of data generated by the CASP study.
CDKAL1 is, thus, the third CD gene (after IL23R and
IL12B) to be convincingly implicated in psoriasis
susceptibility. This suggests a pathogenetic mechanism,
whereby risk alleles at shared disease loci may account
for the increased incidence of psoriasis among CD
patients.32,33
Our results also show that the CDKAL1 SNP confer-
ring susceptibility to TIID is not associated with psoriasis
or CD, thus validating the presence of two independent
association signals at this locus. It is to be noted that the
psoriasis associated SNP (rs6908425), the TIID associated
SNP (rs10946398) and the various markers that are in LD
with them (rs4712528, rs7748720 for rs6908425;
rs9460546, rs9565871 for rs10946398; r240.8 for all) all
map to CDKAL1 intron 5, suggesting that this gene
region may contain important regulatory elements. This
notion is consistent with the annotation data available
through the University of California at Santa Cruz
(UCSC) genome browser, which shows the presence of
evolutionary conserved regions in proximity of both
rs6908425 and rs10946398. In this context, it is tempting
to speculate that the two SNPs may confer susceptibility
to clinically distinct disorders, by affecting regulatory
elements that drive CDKAL1 expression in different cell
types. It should be noted that the existence of CDKAL1
tissue-specific enhancers has already been demonstrated
for a conserved segment of intron 9, which can drive the
expression of a lacZ reporter in the mouse foetal brain
(data generated by Lawrence Berkley National Labora-
tory and available through VISTA whole genome
enhancer browser34).
As the function of the CDKAL1 protein is unknown,
we analysed the gene expression pattern in a wide range
of tissues and cell types. Although our real-time PCR
analysis confirmed previous reports of high CDKAL1
expression in the skeletal muscle, it also generated a
number of novel and significant findings. CDKAL1
transcripts were virtually absent from primary keratino-
cytes, the small intestine and the colon. Conversely, gene
expression was clearly detected in immune cells. A very
strong signal was observed in CD4þ T-lymphocytes,
which are crucial to the pathogenesis of both psoriasis
and CD. CDKAL1 was also found to be markedly
downregulated in activated T- and B-cells, providing
additional support to the notion that its gene product has
an important role in the biology of lymphocytes. Further
studies will now be required to dissect the molecular
interactions underpinning CDKAL1 function in the
immune system.
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